Podcasts about Genetic

What's more British than the British royal family? More Spanish than the Spanish Monarchs? More Norse than the King of Norway? Well, a lot of things actually. In fact, nearly all of the 10 remaining hereditary monarchs of Europe have more German DNA than they do local. For centuries, royals almost exclusively married other, foreign royals. They rarely mixed their blue blood with people native to the Kingdoms they ruled over. What's more, when dynasties died out (often from excessive inbreeding) foreign royal houses put their own seconds sons on the throne, establishing new, entirely alien dynasties. Modern royal families try to brand themselves as throughly native and in touch with the common people. And if they ever spit into a test tube and sent it off for a DNA test, they would probably never publish the results. But, by looking back at their family trees, we can get a pretty good idea of their heritage. So let's find out just when and how the Swedish got so French, the Dutch got Argentinian, and everyone got so German! Royal family of Belgium Royal family of Denmark Princely family of Liechtenstein Grand Ducal family of Luxembourg Princely family of Monaco Royal family of Norway Please consider supporting me at https://www.patreon.com/LindsayHoliday Music: Brandenburg Concerto No4-1 BWV1049 - Classical Whimsical by Kevin MacLeod is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/ Source: http://incompetech.com/music/royalty-free/index.html?isrc=USUAN1100303 Artist: http://incompetech.com/ Join me every Tuesday when I'm Spilling the Tea on History! Check out my Youtube Channel: https://www.youtube.com/c/lindsayholiday Please consider supporting me at https://www.patreon.com/LindsayHoliday and help me make more fascinating episodes! Intro Music: Baroque Coffee House by Doug Maxwell #HistoryTeaTime #LindsayHoliday Please contact ⁠⁠⁠⁠⁠advertising@airwavemedia.com⁠⁠⁠⁠⁠ if you would like to advertise on this podcast. Learn more about your ad choices. Visit megaphone.fm/adchoices

Could your weight gain and non-stop thoughts about food actually come from a rare condition you were born with? In this episode of the Docs Who Lift podcast, Dr. Spencer Nadolsky and Dr. Karl Nadolsky chat with weight expert Dr. Jesse Richards about Bardet-Biedl Syndrome (BBS). This rare condition tricks your brain into thinking your body is starving, even when you have plenty of body fat stored up. They talk about how doctors figure out if someone has BBS, an easy math trick to check your risk, and why normal diets or standard weight-loss shots do not always work for this condition. Plus, you will learn about special medicines that fix the brain's hunger signals when nothing else seems to work! In This Episode, You Will Learn: What Bardet-Biedl Syndrome (BBS) is and why many doctors miss it. Clear physical signs to look for, like extra fingers or toes, vision loss, and weight gain that starts very early in life. An easy formula to check your risk using your weight and your daily thoughts about food. The big difference between normal food cravings and extreme, non-stop hunger. Why special medicines can fix brain signals when regular weight-loss tools fail. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On the same day in July, three different FBI sources gave three different answers about the single most critical piece of evidence in the Nancy Guthrie kidnapping — whether the ransom notes are even real. Tony Brueski goes live to walk through the contradiction: Reuters reporting all the notes are fake, the Phoenix field office saying some may be legitimate, and TMZ's sources ranking the original two as more credible than not. Same evidence, same day, three different stories from inside one investigation. It landed the same week Savannah Guthrie posted a video to her mother's abductor that dropped every demand she'd made for six months and replaced them with something that sounded like she already knows how this ends. Retired FBI Special Agent Jennifer Coffindaffer joins the conversation with her ten-point challenge to investigators — why the enhanced photo of porch guy has never been released, why Nancy's face is on the billboards instead of a suspect's, and the one question nobody has answered yet. Former agent Steve Moore has already called the case cold on camera, predicting fresh eyes will eventually have to rotate in. Genetic genealogy testing on DNA recovered from inside the house began in February. Five months later, if results exist, nobody has shared them. This is a live conversation about what it means when the Bureau can't agree with itself, and a daughter's words move on without them. Links Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/ Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1 Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/TrueCrimePod This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice. Hashtags #NancyGuthrie #FBI #HiddenKillersLive #TrueCrime #JenniferCoffindaffer #Tucson #PorchGuy #RansomNotes #PimaCounty #ColdCase 

Tayne, host of the Tayne Talks podcast, joins me to talk about McBee Dynasty Season 3 Episodes 1-5! Full episode available on Patreon! CLICK HERE TO LISTEN TO THE REST! ACCESS AD-FREE, BONUS AND VIDEO EPISODES BY BECOMING A PATRON HERE⁠⁠⁠⁠ Subscribe to my ⁠YouTube⁠!! Follow Tayne on⁠⁠⁠ ⁠Instagram⁠⁠⁠⁠ and listen to her⁠⁠⁠ ⁠podcast⁠⁠⁠ Follow me on⁠⁠⁠⁠ ⁠Instagram⁠⁠⁠⁠⁠ ⁠Support the show⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

After a summer hiatus, David Brown returns to Angus Underground with longtime friend and repeat guest Dave Mullins for a candid conversation about the current Angus business, the cattle market, and the opportunities facing breeders today. David opens with updates from Montana Ranch before diving into his thoughts on the American Angus Association's Data Driven Herd recognition program, the importance of submitting real-world performance data, and recent changes surrounding genetic testing and AI certificate requirements. While never shy about sharing his frustrations, David's larger message remains consistent: meaningful data collection matters, particularly as genomics continue to play a larger role in cattle evaluation. From there, David and Dave turn to what they describe as an unprecedented cattle market. Despite drought conditions, market volatility, and challenges such as New World screwworm concerns, demand for quality Angus genetics remains remarkably strong. They examine why traditional “sale seasons” are becoming less relevant, with successful production and frozen genetics sales happening throughout the year. Dave explains that today's buyers are increasingly willing to invest whenever the right genetics become available—whether they're looking for embryos for an upcoming IVF cycle, a donor cow to advance their program, or genetics that fit a very specific breeding philosophy. Ultimately, the conversation centers on intentionality. David and Dave encourage breeders to determine exactly what they want their program to accomplish, reverse engineer the path to get there, and resist being distracted by industry noise or someone else's definition of success. Whether a breeder focuses on maternal cattle, performance genetics, carcass traits, show cattle, or another segment entirely, there is room within the Angus breed for different approaches. Their message to both established and young producers is simple: build a good product, communicate clearly why it matters, understand your customer, and become exceptionally good at serving your particular segment of the cattle business. Key Discussion Points The return of Angus Underground after a busy summer at Montana Ranch American Angus Association's Data Driven Herd recognition program Why real-world performance data remains important alongside genomics Genetic defect testing and AI certificate requirements Current cattle inventory and historically strong market conditions New World screwworm concerns and cattle-market volatility Record demand for registered Angus cattle and genetics Why traditional spring and fall “sale seasons” are changing Growing opportunities for year-round embryo and semen sales How IVF has changed the timing of frozen-genetics purchases The diversity of today's Angus breeders and buyers Finding the right customer instead of trying to appeal to everyone Building a breeding program around intentionality and consistency “Reverse engineering” your operation from the outcome you want Why breeders should learn from successful programs—even those with completely different philosophies Opportunities for young people looking to build careers in the cattle industry  

Send us Fan MailThis week we're diving into Deep Blue Sea (1999). We look back on its stacked cast, dissect its balance of creature-feature and ethical sci-fi horror, and debate how its shark approach holds up against the Jaws legacy. This episode contains spoilers, beginning at 21:57.Mentioned in the EpisodeWatch the MovieDeep Blue Sea (1999)Related Episodes⁠024: Scream (1996)⁠097: Alien (1979)⁠162: Jaws 2 (1978)⁠222: Jaws 3-D (1983)⁠279: Jaws: The Revenge (1987)⁠416: Halloween H20: 20 Years Later (1998)Sharksploitation: 50 Years After Jaws (Video)Sharksploitation: 50 Years After Jaws (Episode)Main Episode⁠Sharksploitation: How Jaws Changed Horror and Shark Movies Forever⁠Deepest Bluest (Shark's Fin)⁠How Deep Blue Sea's Most Shocking Death Was Created⁠Cutthroat Island (1995)⁠The Long Kiss Goodnight (1996)⁠Star Wars: Episode I – The Phantom Menace (1999)⁠Sharknado (2013)⁠Frankenstein (1931)⁠Open Water (2003)⁠Piranha (1978)⁠Halloween: Resurrection (2002)⁠Dangerous Animals (2025)⁠Genetic engineering⁠Animal testing⁠Alzheimer's diseaseSupport the showThanks for listening to Hack or Slash! Want more from the show? Join us on Patreon for extended episodes, bonus reviews, B-sides, watchalongs, behind-the-scenes extras, and more ways to help keep the show alive and slashing.Support us on PatreonYou can also hang out with us between episodes in our community spaces. Join the Discord for watch parties, episode discussions, horror recommendations, and general spooky nonsense.Join our DiscordFollow Hack or Slash:WebsiteYouTubeRedditInstagramTikTokHave thoughts on this week's movie? Leave a comment, send us a voicemail, or tag us online. We love hearing your thoughts on the movies we cover.Happy slashing!Music Credits: "Hack or Slash" by Daniel Stapleton

In this episode the guys sit down with IFBB pro bodybuilder and science-driven performance coach Ben Pakulski for a wide-ranging conversation on peptides, performance, identity and the hard lessons of a 20-year bodybuilding career. Ben breaks down the peptide landscape — why he's optimistic about the science but deeply cautious about sourcing (90%+ of research peptides come from China with no quality guarantees), the most exciting peptides he's currently working with including SS-31 for mitochondrial repair, and myostatin inhibition and where the science actually stands. They also cover Ben's origin story — going from 160 pounds at 17 to 240 by 19 purely naturally, getting cut from a baseball team at 12 and how that shaped everything, the culture of his Toronto gym and what hard training actually looks like, the Arnold Classic story where he competed sick all night with vomiting and diarrhea and still got second. Ben shares how bodybuilding was never his identity — just something he did — and why leaving the sport felt like relief rather than loss. They also dig into GLP-1 use, the looming frailty epidemic, genetic testing for coaching, why the guys fixed their training plateaus through gut health and hormone optimization, and why Ben thinks the hard work of getting fit is the actual prize — not the physique.   MAPS Upper Lower: https://mapsupperlower.com Code: LAUNCH for 40% off. Two days left on this offer. Four day split, male and female versions, workout videos and live coaching with Cole.   SPONSORS Ketone IQ: https://ketone.com/MINDPUMP 30% off subscription orders plus a free gift with your second shipment. Also available at Target stores nationwide.   GUEST LINKS Ben Pakulski: https://www.benpakulski.com Ben's Podcast — Muscle Intelligence: available on all major platforms Instagram: @bpakfitness   LINKS Mind Pump Store: https://mindpumpstore.com Maps Fitness Products: https://mapsfitnessproducts.com Instagram: @mindpumpmedia 0:00 - Intro 1:58 - The peptide landscape — incredible potential, serious sourcing risk 5:14 - SS-31 for mitochondrial repair and why Ben's dad is on 10mg three times a week 9:04 - Mots-C vs SS-31 — why people respond differently and what might explain it 10:17 - Myostatin inhibition — what the science actually says about building muscle without training 13:32 - Gene therapy for myostatin in Mexico and what Ben's friends actually reported 15:28 - Why putting on muscle through shortcuts doesn't build confidence — only the process does 17:54 - Why physical stress and psychological stress are disconnected in modern life — and why that matters 22:05 - Getting cut from a baseball team at 12 and how that shaped everything 24:06 - The four master skills Ben teaches his kids — body, finances, communication, emotions 25:51 - How Ben transitioned out of pro bodybuilding without an identity crisis 28:58 - Going from 160 to 230 pounds naturally at 17 — the real story 33:01 - Getting a Muscle Tech contract at 19 by just walking around a show 38:03 - Training culture at Gold's Venice vs his Toronto gym — what hard work actually looks like 43:36 - Why headphones in the gym killed community — and why CrossFit understood something bodybuilding missed 48:24 - The Arnold Classic sick story — vomiting all night, competing anyway, getting second 55:28 - First steroid cycle at 19 and what it actually did 1:02:43 - How Ben's business pivoted through Covid and why coaching replaced digital programs 1:06:32 - Warrior and monk — how Ben learned to wield intensity as a tool rather than let it control him 1:13:06 - GLP-1 use in bodybuilding, the looming frailty epidemic and the gut motility problem 1:23:07 - Genetic testing for coaching — seeing constraints before clients hit them 1:31:05 - Sal's gut health and testosterone story — 15 pounds of muscle from a parasite cleanse

Stay informed on current events, visit www.NaturalNews.com  - Fauci's Depopulation Agenda and Biological Weapons (0:10) - Government Lies and Radiation Risks (4:31) - Fauci's Testimony and Fifth Amendment Invocation (11:48) - Trump's Role in the Depopulation Agenda (23:33) - The Depopulation Agenda and the Role of the Military (1:03:35) - The Impact of Nuclear War on Humanity (1:03:47) - The Role of AI and the Future of Humanity (1:03:59) - The Global Energy War and Its Consequences (1:05:31) - The Role of Technology in Survival (1:05:44) - The Importance of Self-Reliance and Preparedness (1:13:36) - Europe's Economic Collapse and Geopolitical Tensions (1:15:34) - The Role of Young Men in the Conflict (1:22:02) - The Impact of Nuclear War and COVID-19 Vaccines (1:25:56) - The Future of Humanity and Technological Advancements (1:33:01) - Preparedness and Survival Strategies (1:39:56) - The Role of Local Law Enforcement and Community Support (1:40:11) - The Ethics of Self-Defense and Protecting the Innocent (1:41:08) - The Importance of Training and Skill Development (1:49:26) - The Role of Technology and AI in the Future (1:49:40) - Final Thoughts and Call to Action (1:50:37) Watch more independent videos at http://www.brighteon.com/channel/hrreport  ▶️ Support our mission by shopping at the Health Ranger Store - https://www.healthrangerstore.com ▶️ Check out exclusive deals and special offers at https://rangerdeals.com ▶️ Sign up for our newsletter to stay informed: https://www.naturalnews.com/Readerregistration.html Watch more exclusive videos here:

In this conversation, Dr. Gladden and Annelie Smith explore the intersection of genetics and nutrition, emphasizing the importance of personalized approaches to health. They discuss the evolution of nutrigenomics, the role of AI in developing tailored health plans, and the complexities of hormonal balance as influenced by genetics. Annelie shares insights from her clinical experience, highlighting the need for a systems biology approach to understand the intricate relationships between genes, hormones, and overall health. The discussion also touches on future directions in genetic testing and the potential for more accessible and actionable insights for individuals. In this conversation, Dr. Gladden and Annelie Smith delve into the complexities of hormone replacement therapy, emphasizing the importance of understanding hormonal pathways and the role of genetics. They discuss how stress impacts hormonal balance and the significance of reprogramming the nervous system for better health outcomes. The conversation also highlights the relevance of nutrigenomics in personalized nutrition and the powerful benefits of sulforaphane. Finally, they explore the value of genetic testing for optimizing health and wellness.   For Audience Join the other 20,000+ high-performers getting weekly insights on biological reversal, exponential strategies, and Life Energy optimization→ https://start.gladdenlongevity.com/subscribe If you're ready to measure your 60+ biological ages and build a personalized reversal plan, apply for a discovery call here → https://start.gladdenlongevity.com/apply-now   Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/!    Takeaways ·       Nutrigenomics provides insights into personalized nutrition. ·       Understanding genetics can enhance dietary recommendations. ·       AI is transforming the landscape of personalized medicine. ·       Systems biology offers a holistic view of health. ·       Patient engagement is key to successful health interventions. ·       Genetic testing can reveal vulnerabilities in health. ·       Hormonal balance is influenced by genetic factors. ·       Personalized health plans can improve patient outcomes. ·       The future of genetics holds promise for broader applications. ·       Access to genetic information can empower individuals. Hormone replacement therapy is complex and requires a systems approach. ·       Understanding genetic pathways is crucial for effective hormone management. ·       Stress significantly impacts hormonal balance and overall health. ·       Reprogramming the nervous system can alleviate stress and improve health. ·       Nutrigenomics plays a vital role in personalized nutrition. ·       Sulforaphane is a powerful compound with numerous health benefits. ·       Diet should be tailored to the individual, not a one-size-fits-all approach. ·       Genetic testing provides valuable insights for health optimization. ·       Managing stress involves rebuilding mental constructs that generate it. ·       Investing in genetic testing is a one-time opportunity with lasting benefits.    Chapters 00:00 Introduction to Nutrigenomics and Personalization 02:49 The Role of Genetics in Nutrition 06:01 Systems Biology Approach to Health 08:55 AI in Nutrigenomics and Personalized Medicine 11:51 Case Study: Hormonal Balance and Genetics 14:59 Future Directions in Genetics and Health 23:35 Understanding Hormone Replacement Therapy 26:16 The Complexity of Hormonal Pathways 28:26 The Role of Stress in Hormonal Balance 30:22 Reprogramming the Nervous System 32:37 Nutrigenomics and Personalized Nutrition 36:27 The Power of Sulforaphane 39:04 Exploring Genetic Testing for Health Optimization To learn more about Annelie Smith:Email: annelie@3X4.io   Website: www.3X4Genetics.com   Reach out to us at:    Website: https://gladdenlongevity.com/     Facebook: https://www.facebook.com/Gladdenlongevity/    Instagram: https://www.instagram.com/gladdenlongevity/?hl=en     LinkedIn: https://www.linkedin.com/company/gladdenlongevity    YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw    

What if a single urine sample could screen for 50 diseases before you ever felt sick? Dejan Nenov, co-founder of AI diagnostics company Luventix, joins Dr. Joy Kong to explain how.Dejan Nenov has spent nearly a decade navigating FDA processes and clinical trials, and also founded Panaton, a healthcare IT company connecting hospitals, labs, and clinics across the US. Luventix uses machine learning to analyze 38,250 raw chemical data points in a single urine sample, identifying disease patterns without isolating a specific biomarker first. Its ongoing IRB-approved study covers roughly 1,250 patients across colorectal cancer, Crohn's, celiac disease, and SIBO. The same model can predict which patients will respond to a given treatment, a tool called companion diagnostics, and could eventually screen for dozens to hundreds of conditions from one low-cost sample. Dejan and Dr. Joy also cover the regulatory pathway for AI diagnostics, including the FDA's Lab Developed Test framework, and how genetics and metabolomics offer two different, complementary pictures of health.The conversation also covers a personal case: a close friend's daughter whose rare condition took years and specialists across ten states to diagnose, and why Dejan believes AI could have caught it sooner.Dr. Joy and Dejan close with what a fully AI-run hospital already looks like in China, and Dejan's vision for an at-home test, like a pregnancy test, that catches disease three to eighteen months before symptoms start.Dejan talks about:00:00 How a dog's nose inspired Luventix03:58 A dog's nose as a gas chromatograph04:22 Training AI to classify disease05:25 The 450-patient GI cancer trial06:54 Urine reflects the body's metabolic state08:07 Skipping biomarkers, reading raw data patterns11:00 38,250 data points per urine sample13:22 Metabolomics plus genetics, a fuller picture16:44 The single 50-disease urine panel18:51 FDA pathways: PMA vs. lab-developed tests22:20 Regulating AI models that keep improving36:11 Catching disease 18 months earlyAdditional Resources✨ Learn more about Luventix: https://www.luventix.com/ ✨ Read more about how AI offers an alternative to genetic testing: https://www.luventix.com/blog/ai-offers-alternatives-to-genetic-testing-to-make-disease-detection-more-accessible Visit My Clinic: Chara Health

In this episode of The Lead, host Tina Baykaner, MD, MPH, is joined by Christopher Kowalewski, MD, and Marco Perez, MD, to discuss the journal article, Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP Study. Together, they review findings from this secondary analysis of the LOOP Study and explore the relationship between genetic risk and atrial fibrillation screening. Learning Objectives Review the key findings from the secondary analysis of the randomized LOOP Study examining atrial fibrillation screening according to genetic risk. Discuss the relationship between genetic risk and atrial fibrillation screening as evaluated in the study. Explore the potential implications of incorporating genetic risk into atrial fibrillation screening strategies.   Host: Tina Baykaner, MD, MPH Guests: Christopher Kowalewski, MD and Marco Perez, MD   Disclosures: T. Baykaner Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific Research: NIH, Boston Scientific   C. Kowalewski No relevant disclosures   M. Perez Ownership/Partnership/Principal: QALY Honoraria/Speaking/Consulting Fee: Boston Scientific, Biotronik Research: Apple, Inc. Other/Stock Options Privately Held

In this special rerun episode of The Dairy Nutrition Blackbelt Podcast, Dr. Pedro Melendez, Clinical Full Professor at City University of Hong Kong, explains how abdominal adiposity and hypocalcemia affect transition cow health. He discusses genetic links to internal fat, risks of metabolic disease, urine pH monitoring, anionic diets, and the use of calcium boluses for older cows. Listen now on all major platforms!"Excess abdominal adiposity can trigger lipolysis, inflammation, mastitis, ketosis, and fatty liver while reflecting an important genetic component."Meet the guest: Dr. Pedro Melendez is a Clinical Full Professor in Bovine Production Medicine at City University of Hong Kong. He earned his DVM from the University of Chile and his MS and PhD from the University of Florida, with work focused on dairy production medicine, nutritional management, and metabolic disease. Learn more from Dr. Pedro Melendez on The Dairy Nutrition Blackbelt Podcast, available on all major platforms.Liked this one? Don't stop now — Here's what we think you'll love!What will you learn: (00:00) Highlight(01:44) Introduction(02:14) Guest background(03:30) Abdominal adiposity risks(06:41) Genetic factors role(08:14) Preventing hypocalcemia(10:49) Calcium bolus use(12:08) Closing thoughtsThe Dairy Nutrition Blackbelt Podcast is trusted and supported by the innovative companies:* Fortiva* Adisseo* Vetagro* Barentz* Priority IAC* Kemin- Esmilco Inc.- Virtus Nutrition- DietForge

Happiness is the enemy of the future. Happiness is like a mirage in the desert; it eludes your grasp when you most strive for it. And yet, in my first book, I wrote about how…“I've found the happiness that I didn't give a damn about…”Here I'll break down why not giving a damn about happiness makes you happier, quantitatively and qualitatively. To illustrate the principle of “hedonic adaptation,” I'd like you to think about going on an awesome vacation...01:01 The Genetic and Biological Roots of Happiness02:00 Hedonic Adaptation and Vacation Fatigue11:16 The Impact of Hedonic Adaptation on Life Satisfaction16:36 Boredom with Pleasure and the Search for Meaning19:58 Making Meaning the Compass in Life24:15 The Genetic Purpose and Parenthood as Happiness34:31 Spirituality, Superstition, and Deep Happiness38:04 Gratitude as a Practice for Lasting Happiness40:56 Epicurean Living and Community44:16 Reframing Happiness as the Absence of Suffering47:13 The Ultimate Pursuit: Meaning Over HappinessFor every mentioned here, read: Don't give a damn about happiness

Two years after researchers identified ReNU syndrome, where are we now?   In 2024, two independent research teams identified the genetic cause of ReNU syndrome, a rare neurodevelopmental condition affecting thousands of people worldwide. The discovery marked the beginning of a new chapter for families searching for answers and opened up exciting new avenues for research.  In this episode, host Sharon Jones revisits the story to explore what has happened since that breakthrough. She is joined by: Professor Nicky Whiffin, Associate Professor and Wellcome Career Development Fellow at Big Data Institute and Centre for Human Genetics, University of Oxford Christina Cox, Co-founder of ReNU Syndrome UK and parent of a child with ReNU syndrome Dr Ana Lisa Tavares, Clinical Lead for Rare Disease at Genomics England Together, they discuss how researchers around the world have built on the original discovery to deepen our understanding of ReNU syndrome, why studying the non-coding regions of our DNA is revealing previously unknown rare conditions, and how collaboration between researchers, clinicians and families is accelerating progress. They also explore how the growing ReNU community is supporting newly diagnosed families and what the future could hold for new treatments.  Links:  Previous episode detailing the discovery of ReNU Syndrome  ReNU Syndrome UK's website  Original research paper from Nicky's team in Oxford  Original research paper from the team based in New York   “It's been only two years since our paper came out about this, and in that time, there are now patient family groups that have been set up all around the world. There is the one in the UK led by Christina and the others. There's the one in the US that's led by a group of four women, and there are ones in France, Spain, like, literally all around the world. And all of these groups are also somewhat coordinated. The leads of these groups meet with each other. They've organised meetups. I've been to ones in the US, the UK, and in France. So the fact that they can mobilise all of that and create such a community so quickly is absolutely incredible.”  You can download the transcript, or read it below. [00:00:00] Sharon: In 2024, two independent research teams identified a genetic cause of a rare neurodevelopmental condition affecting thousands of people around the world. Since then, that initial groundbreaking discovery has grown into something much bigger, bringing together families, researchers, and clinicians, and building a clearer picture of what we now know as ReNU syndrome.  [00:00:26] Sharon: Welcome to Behind the Genes, the podcast that covers everything from cutting-edge research to real-life stories in genomic healthcare. I'm Sharon Jones, and in today's episode, we're looking at what's happened since that discovery, what researchers are continuing to learn, and what the future could hold for people living with  ReNU Syndrome and their families.  [00:00:46] Sharon: To help us understand more, I'm joined by Professor Nicky Whiffin, Christina Cox, and Dr. Ana Lisa Tavares. So, two papers were published around the same time for this condition. To start us off, Nicky, you worked on one of these papers. Could you explain how this journey first began?   [00:01:05] Nicky: Yeah, so this was two years ago now, back in early 2024, where two research teams, so us based in Oxford and a, a group based in New York, were both looking at the data within the National Genomics Research Library, and we both kind of somewhat simultaneously found that there was variance in this very, very small gene, it's called RNU4-2, were found in individuals with previously undiagnosed neurodevelopmental disorders.  [00:01:39] Nicky: And this was very, very striking because we initially actually identified the same single DNA change or mutation in 40 or so different individuals within the National Genomics Research Library, and we normally expect to see a whole host of different variants. We don't expect to see the same one.  [00:01:59] Nicky: So this was a really, really surprising finding. And it was through a collaboration, large scale collaboration across the world where we started contacting our other collaborators who have similar collections of patients who have been genome sequenced to ask if they had any individuals with DNA changes in this gene.  [00:02:17] Nicky: And we found some in the US, some in, in Australia, some in France and Germany. So very, very quickly built up this, this complete picture of variants in this gene, causing this rare neurodevelopmental disorder   [00:02:35] Sharon: of people finding it at the same time, what, what did that feel like?  [00:02:39] Sharon: Like, give us a ense of, like, that compelling, "We think we found something." What was that like?   [00:02:46] Nicky: I didn't believe it initially. You're always told when you're a scientist that if it looks too good to be true, it's, it's not true, and this basically lit up like a beacon. There's this particularly one DNA change that we found in, um, I think it was about 40 different individuals, and we don't really expect that to be the case.  [00:03:04] Nicky: We normally expect these genetic variants to be somewhat randomly distributed across the genome. So to find 40 individuals with exactly the same DNA change was very, very surprising. So initially, I didn't believe it. The whole team, including folks at Genomics England, spent a lot of time trying to check that these variants were real and tried to disprove the result, tried to find any other way in which any other reason why we would be seeing this.  [00:03:31] Nicky: And after a little while, we had to concede that we couldn't disprove it, so it must be true, and that, that was a very exciting moment.   [00:03:38] Sharon Jones: Was it the case that over in the States, the exact same thing was happening?   [00:03:42] Nicky: I think we found out when we were both speaking at the same conference, actually. So we didn't actually know that we, that we'd both come across the same result.  [00:03:49] Sharon: If you want to check out our previous episode on this initial discovery, you'll find a link to it in the episode description.  [00:04:00] Sharon: So Christina, tell us a bit about your situation, your family situation, and for our listeners, what ReNU is.   [00:04:05] Christina: So ReNU is, to us, is a family. We got a family when we got diagnosed with  ReNU. Beau - Arabella - already had other diagnosises, but people had always said to us, "Oh, there's something else. There's something else.  [00:04:20] Christina: We're not sure what it is, but there will be something." And then when we got  ReNU, it was like, "Oh, okay, amazing. What do we do? What is it?" Because there was only four lines on Wikipedia when we first got told about it, and there wasn't anything that, ourselves could find. So we kind of went onto Facebook and looked for groups and different people, and there wasn't really anything except for Jess in America.  [00:04:46] Christina: And then it grew, and then it kind of, we ended up finding more people in the UK and, like, all over. But for us, it didn't really change how we perceived Beau. It just made life easier. Like, knowing there was other families out there that we could find advice from and support from, and that we kind of knew what we had and going forward then, like, finding researchers and connecting with everybody.  [00:05:15] Sharon: Yeah. And for those who don't know, can you talk about what  ReNU is? Like, how does it affect Beau?   [00:05:20] Christina: So with Beau and  ReNU , it affects her with developmental delay. She's non-verbal. She's incontinent. She suffers for walking, so she can do a little bit of walking, but she needs a wheelchair It affects her mood swings.  [00:05:38] Christina: It just affects everything. Although she has it, she's still a happy, outgoing, very stubborn, just kind of "keep-going" child. But it affects her in everything, like eating, sleeping.   [00:05:51] Sharon: It sounds like life is, you know, very challenging on a day-to-day basis, lots of considerations. How did you feel when you finally got this diagnosis after years of wondering and waiting, not knowing?  [00:06:02] Christina: Finding out was, like, really emotional because it was like, "Oh, wow, so we have this diagnosis. Now what? What are we looking for? What's going to happen?" And then we were kind of like, "Oh, but there's not many people that had it." Because we found out in the August, so then it was trying to find people. But it has been life-changing to know that we're not on our own and that there is other people around.  [00:06:28] Sharon: Yeah, tell us a bit more about that. How did it feel to get that diagnosis?   [00:06:32] Christina: It was quite strange because our pediatrician rang us and said, "Oh, we've got a diagnosis. She's got RNU4-2." And we were like, "Okay, so what's that?" And she's like, "I don't really know. There's four lines on Wikipedia at the moment."  [00:06:46] Christina: She goes, "I don't like Wikipedia," but we still kind of... That was it. So then we went on a mission to find and look for where we could find support and find other families.   [00:06:58] Christina: At that point, I didn't know of anybody in the UK, and my husband found Jessica in America. What then, kind of, we had somebody to talk to, and then families in the UK kind of started appearing.  [00:07:09] Christina: So we ended up getting a whole network of people to bounce ideas off and talk about how it affects their children and what's for the future and things like that. It was really nice.   [00:07:22] Sharon: Yeah, yeah, I can imagine. So Ana Lisa, how do these findings contribute to a growing understanding of the condition?  [00:07:29] Ana Lisa: So this was an amazing discovery. Although we're finding new rare conditions quite often, not on this sort of scale. It was also an amazing finding because a lot of the genes that we know are associated with rare conditions are genes that encode proteins, and in the 100,000 Genomes Project, we were doing whole genome sequencing, and Nicky and her team were looking in the parts of the genome that don't encode for proteins.  [00:08:03] Ana Lisa: And so this was, uh, exciting from that point of view as well. So the vast majority of our genome, more than 98%, does not encode for proteins, but it's relatively unexplored. And if we think about our genome and the letter code that makes it up, which is the manual for how our bodies are built, and grow and function day-to-day.  [00:08:30] Ana Lisa: Those 3 billion letters, if you, if you printed them out in a 12 font regular print, it would stretch so far you could fly, I think, from London to Paris several times, maybe three times or something. And so, this actual gene is a very, very small gene, less than 150 of those letters. So again, it was incredible to find that by comparing across many, many different genomes in the National Genomic Research Library.  [00:09:00] Ana Lisa: Going back to your question about a growing understanding of a condition, it was a completely new condition, but it also opened up looking at other related genes and actually now more disorders that are being found, like RNU2-2 by colleagues in the US, and that might be one of the most common recessive genetic neurodevelopmental disorders.  [00:09:27] Ana Lisa: So it's really, really opened up this understanding about these types of disorders and also those non-coding parts of our genome and the power of collaboration and being able to look across many different whole genomes at the same time.   [00:09:44] Sharon: Yeah. And Nicky, you've been involved in much of this research journey.  [00:09:50] Sharon: What have been some of the biggest advances or learnings for you so far?   [00:09:55] Nicky: I think the biggest one is just how common, or how frequent, these disorders are. So what we discovered recently in terms of new genetic disorders were rarer and rarer conditions, and that's why we hadn't seen them before. But from going from looking at the protein coding genes to looking at these non-coding genes, we found something that was as frequent as disorders that were found in the early 2010s when we first had large-scale sequencing projects that looked at the protein coding genes.  [00:10:26] Nicky: So that was really, really surprising. And we now know there's this whole class of disorders. So RN4-2, this gene encodes this -- Well, it produces this small RNA that works in this huge molecular machine that is called the Splicer Zone, that mediates the processing of most of the other genes across the genome.  [00:10:50] Nicky: And there are lots of these little RNAs that work in this molecular machine that are called the small nuclear RNAs or the snRNAs And we now know that there are a whole multitude of different disorders associated with different ones of these spliceosomal small nuclear RNAs, and that's really incredible.  [00:11:09] Nicky: And for RNU4-2 itself, we also now know that there are, there's not just RENE syndrome, uh, which is a dominant disorder caused by chance de novo variants that are newly arisen in a child, but also a recessive disorder where a child inherits one, uh, gene mutation from each parent. And also another finding that there is a region of the gene where we find DNA changes that cause retinitis pigmentosa, so a retinal phenotype. So we now know a huge amount more about this single gene, but also all of this different class of genes or RNAs that work in the same molecular machine, uh, which is, is really fascinating biologically   [00:11:52] Ana Lisa: Vicky, while you were talking, I was thinking about the splicing and how a bit like this podcast recording, you're going to splice out the kind of extreme, the noise that wasn't supposed to be there.  [00:12:03] Ana Lisa: And actually, you could make slightly different versions of this podcast, couldn't you? And that's, that's what, what's happening in our bodies for a lot of our genes that, that the kind of output can be varied slightly.   [00:12:15] Sharon: So Christina, how has collaboration been involved across the community and with researchers?  [00:12:21] Sharon: You know, what sort of things have you been doing?   [00:12:23] Christina Cox: So it's amazing to have researchers that are so open and amazing to work with the families. So at the moment, we are just putting together like a panel to discuss questions from families, to then be able to answer families, to work very closely with the researchers for what things are happening and the progress within.  [00:12:47] Christina: It's just amazing to be able to work with researchers. They're just fantastic.   [00:12:52] Sharon: And from what I understand, like, you, you have a charity, don't you? Can you tell us a bit more about that and how that came about?   [00:12:58] Christina: So we have ReNU Syndrome UK, and it came about as there was a group of us parents that were like, we wanted to be able to support other families, knowing what it was like for us when we first started.  [00:13:12] Christina: It was very difficult. So we wanted to start a charity that can support families and signpost them, give them the opportunity to have family meetups once or twice a year, so we can work with scientists and specialists to keep everybody in the community, like the ReNU family, up to date. But being able to connect with so many families, because a lot of the doctors don't really know of ReNU Syndrome yet.  [00:13:46] Christina: So if we have a problem or a question, we put it in the WhatsApp group, and then somebody can answer it because they've been through it, or they, they've just asked the question. So it's just an amazing resource for everybody   [00:14:02] Sharon Jones: That sounds amazing, and it sounds like you've all obviously become experts by experience.  [00:14:04] Sharon: So, like you say, you kind of know more, you know, as the science develops, but you're living it every single day   [00:14:10] Christina: It's kind of, you go into the hospital and they're like, "Oh, what's ReNU Syndrome?" And then you're like, "Ugh." So, then you just have to say it all. But, and then it's kind of them bringing, teaching new people who don't know about it in the medical professional.  [00:14:26] Christina: We always give them the website so that they can go and then find, but being able to put more medical stuff on the website, it just helps everybody, and it's just broadening it out to as many people as possible. Because there's still a lot of people undiagnosed with RNU syndrome. It's, now it's easier to be signposted, but it's just keeping that connection.  [00:14:49] Sharon: Yeah. And, and from what I understand, it's got quite an interesting sort of origin of a name, RNU. Where did that... Do you know much more about where that came from?   [00:14:57] Christina: So, Nicky is the amazing person who, um, sorted the name and um, the origin. So, I'll pass that over to Nicky to answer that question because she's just amazing   [00:15:11] Nicky: Uh, so the name ReNU syndrome is an interesting story.  [00:15:13] Nicky: So, a lot of disorders or diseases are named after people. So, we all know Alzheimer's, Parkinson's, etc. And they're often scientists or clinicians that have spent a lot of time working on them. I think that's a little bit odd. I don't think it's the first thing that somebody should know about a disorder, is the name of somebody who's, who's worked on it or studied it.  [00:15:36] Nicky: But they're a very, it's very hard to find an alternative. When we were initially doing the press release around our paper, we had a quote from one of the mothers, Nicole Cedar, who has a, a wonderful daughter called Mia Joy, and she said that within their family, they like to refer to RNU, to RNU4-2 as ReNU, which is a really nice play on the RNU in the gene name.  [00:16:00] Nicky: So then I had an idea, okay, let's just change the spelling to make the, the kind of big R, little E, large N-U, then it would link to the gene name, but also would be a name that speaks to hope and the renewed hope of being given a diagnosis.   [00:16:13] Sharon: Yeah, absolutely, and that's a great, a great story and a great way of kind of making it feel like there is, there is always hope.  [00:16:20] Sharon: So, you know, Nicky, you're now part of the patient community. In a way. You know, so how does it feel to be on that other side of it from that sort of research perspective and now kind of, you know, in that, in that community?   [00:16:34] Nicky: It's amazing. I've got a new family as well. It's not, not just Christina and everybody.  [00:16:39] Nicky: I kind of, I'm a, a basic scientist. I'm not a clinician. Up until this point, we've always been one or two steps removed from actually interacting with the families themselves. Um, so my life has changed an awful lot over the last couple of years, uh, where now, um, I kind of talk to Christina or the folks in the US, really regularly, kind of on a weekly basis.  [00:17:02] Nicky: Um, so that's really different. And I just kind of want to highlight just what these families have achieved. So it's been only two years since our paper came out about this, and in that time, there are now patient family groups that have been set up all around the world. There is the one in the UK led by Christina and and the others.  [00:17:26] Nicky: Um, there's the one in the US that's led by a group of four women, and there are ones in France, Spain, like, literally all around the world. And all of these groups are also somewhat coordinated. The leads of these groups meet with each other. They've organised meetups. I've been to ones in the US, the UK, and in France.  [00:17:46] Nicky: So the fact that they can mobilise all of that and create such a community so quickly is absolutely incredible. And they've got families, they've got so many researchers that are interested in the cause. They're interacting with the pharma companies. They've upskilled themselves to learn so much about genetics.  [00:18:04] Nicky: And it's just an absolutely incredible thing to watch. They're so, so inspiring.   [00:18:09] Sharon: And from what I understand, Christina, you feel, you know, very passionate about Nicky in the same way, about your paths crossing in this way.   [00:18:16] Christina: Oh, my, yes. Every time I see Nicky, I've met her a couple of times, like, in person now, I just cry.  [00:18:22] Christina: I literally, we saw her at the UK meetup, and she walked in the door, and that was it. I was done. I was like, it's just meeting somebody who has changed so many lives and brought a community to other families. It's just amazing. And the support that Nicky's giving us weekly, daily, is just amazing. It is just life-changing for all of us.  [00:18:49] Sharon Jones: It's such a powerful connection. So Ana Lisa, why is collaboration between researchers, clinicians, and families so valuable in the rare disease research space? You know, and what role do large scale research projects and data sharing play in discoveries like this?   [00:19:06] Ana Lisa: Collaboration is completely incredibly valuable and for progress in the rare disease space where there's just so much still to learn.  [00:19:16] Ana Lisa: So more than half of patients and families where, uh, they're seeking a potential diagnosis, we're not yet able to, to find one, and there's so much yet that we still need to learn, and collaboration in so many different spaces and directions and across different spheres enables this progress. So for example, the fact that we have a really connected, uh, National Health Service and really close working between the NHS and Genomics England so that we can, for those patients and families that, that consent to their de-identified data being shared in the National Genomic Research Library, be able to work with many, many different researchers, uh, whether they're academic, institutions, industry, and try and find all the patients that could benefit from a new diagnosis and, uh, potentially new therapies in future clinical trials.  [00:20:21] Ana Lisa: And without that collaboration, it would be really, really hard to find all those people So because we sort of have a clinical research interface where we can go back to clinical teams and therefore to patients and families, even if there's a really, really ultra-rare condition with very few people known to have it that could be under different specialties in different regions, we would be able to contact their clinical team.  [00:20:51] Ana Lisa: So I think that, that collaborative working with the NHS is really powerful across researchers worldwide. Like in this example where a group in Oxford and a group in US were able to make this finding and then all the other findings that are coming from it. And really, without being able to compare across thousands of genomes, one wouldn't have been able to see this, this particular signal and see that there were more than 100 patients, and that was really powerful.  [00:21:20] Ana Lisa: If you just had one genome, you could never have made this novel discovery. I think the other thing is that, and Nicky will say that, you know, she, she then contacted her collaborators who also had access to, to, to data that had been shared by other families and could compare. And again, it's a whole sort of network across the globe.  [00:21:41] Ana Lisa: And we know that there are going to be many more diagnoses to be found. But also, um, I think collaboration will allow us to find new, new treatments. So if we can start to design treatments that target the DNA and RNA at, at source, then actually you could collaborate and say, "Well, this type of genetic mechanism could be targeted in the same way, potentially across even more than one rare condition and reach even more patients."  [00:22:13] Ana Lisa: And actually the power of collaboration across the ecosystem is that hopefully we'll end up with a pathway that can actually go from finding a new genetic finding, like Nicky and her team made, to helping all the people who could benefit from a diagnosis, having one, and then can one develop a treatment and get it to as many patients?  [00:22:42] Ana Lisa: And, and I think that will really demonstrate the power of collaboration.   [00:22:47] Sharon: Yeah. Absolutely, and it can only, you know, benefit those families who have to wait such a incredible amount of time.   [00:22:55] Ana Lisa: There's been such a diagnostic odyssey, and as more diagnoses are made, it becomes obvious that there's, uh...  [00:23:03] Ana Lisa: and it was, it's already well-described, the therapeutic odyssey. Um, but hopefully these sort of novel understanding of our genome and opening up new biological avenues to treat, um, hopefully will also enable many more new treatments to be developed.   [00:23:21] Sharon: Absolutely, and that is the key word there is, is that hope.  [00:23:24] Sharon: So, so looking ahead, Nicky, what developments are you most hopeful about over the next few years?   [00:23:31] Nicky: That's a difficult question. There's so much, so much happening. One thing is that we are gearing up to do large scale studies across the world to understand more about the progression of ReNU. So you might call them large scale natural history studies or just large scale profiling studies where we can do a range of different tests on ReNU patients and, and monitor them over time.  [00:24:02] Nicky: So do those at regular, regular intervals over time so we can see what the progression looks like. And that's really important for trying to think about whether we can treat RNeU syndrome. And on that note, I'm very also excited about the potential for therapeutics. There's lots of people all around the world, both, uh, in academic settings, but also in pharma companies trying to work out whether this is something that we can treat.  [00:24:30] Nicky: There's some very promising early data to show that we can selectively remove the RNA containing the mutation from cells, uh, leaving the copy of the RNA that doesn't contain the mutation intact so that can do the correct function. And biologically, we think this should be an effective treatment.  [00:24:54] Nicky: Um, so we can do that in cells in a dish. We don't yet know whether we can do that in a patient with ReNU. Uh, but that's really, really promising early data. Um, so I'm very hopeful about where that, those studies might lead.   [00:25:08] Sharon: And Ana Lisa, what role will genomics continue to play in improving understanding and care for rare conditions like this?  [00:25:15] Ana Lisa: So following on from what Nicky said, I think the really big hope is that we will be able to develop many, many new treatments collaboratively across the world. And whether these are individualised treatments made for one patient but then shared because we can find perhaps other patients who could benefit from the same treatment, whether we understand the genetics better so that we can design treatments from the start that will work for a lot of patients.  [00:25:46] Ana Lisa: So I think there will be sort of fancier and fancier ways of targeting rare conditions. And right now we're in a phase where the ecosystem is trying to work out how could we make an end-to-end pathway with initiatives like the Rare Therapies Launchpad in the UK, and that's going to require truly collaborative working.  [00:26:08] Ana Lisa: No single organisation can do that. And I think having these incredible use cases will be really powerful for turbocharging the development of these pathways. And the hope is that once you've worked out how to do this across a range of different rare conditions, that one might reach a stage where one could do that a lot faster for many other rare conditions.  [00:26:35] Ana Lisa: Because at the moment they're so underserved in terms of treatments available and there's a huge gap between being able to make a genetic diagnosis and then having treatments. The big hope is that understanding the genetics better will help to open up new pathways to treatment. I do hope that we'll also understand other aspects.  [00:27:02] Ana Lisa: So for example, it might be that understanding the genetics better also helps us to understand different ways a condition might manifest in somebody, why it may be different from one person to another, why somebody might be more mildly affected and somebody perhaps more severely. And that might, may also help us to understand ways to treat a condition by getting, gaining these insights which are, are useful in and of themselves and may also lead to new therapeutic, uh, possibilities.  [00:27:36] Ana Lisa: I think that would be one of my hopes that a lot of these areas overlap and lead to real benefit for patients and families, that we can translate that hope into concrete improvements in treatment for rare conditions.  [00:27:57] Sharon: Do you have a sense of time, how long you think this could all take, that amount of collaboration?  [00:28:06] Ana Lisa: Yeah, and I think this is actually another reason why sometimes it's quite tricky to make progress in this area because being able to predict those timelines is notoriously difficult when you look back historically. I'd like to hope that we're on the cusp of having an explosion of novel treatments that can target DNA and RNA, for example, or treatments that target something in the underlying biology that we now understand that we didn't before.  [00:28:34] Ana Lisa: And I do think that there is going to be a big shift. But I think that the sort of confidence intervals around how big that range of time might be is very hard to predict. And that's why I think Christina and Nicky being able to share these stories and about their collaborative working really shines a spotlight on, on what could be done and how progress can happen.  [00:29:02] Ana Lisa: That's really exciting. The other day at a conference, someone from industry stood up and said, "Oh, actually, we set up a clinical trial in the UK because we knew there were patients who could benefit from our work in the National Genomic Research Library," and that was really exciting for us because that's what we want to do; move forwards the opportunities for treatment for patients.  [00:29:28] Sharon: And so finally, Christina, as a parent and member of this community, what are your hopes for the future, and what would you say to families who may still be searching for answers today?   [00:29:39] Christina: It is a long journey, but there is the support and the help out there. If you have any inclination that you think you might have ReNU, reach out to your paediatrician or your doctor to see if you can get your genetic testing done because it's fighting to get the test, to go to people and say, "I think this is what we may have. Can we look into getting it tested?" And reach out to other families and the website and things because it's all about community and supporting and helping people find that diagnosis.   [00:30:16] Sharon: Thank you, Christina, and we'll put the website in the episode description. A huge thank you to Professor Nicky Whiffin, Christina Cox, and Dr. Ana Lisa Tavares for joining me today and sharing their insights and experiences. To learn more about ReNU Syndrome, visit renusyndromeuk.org. If you'd like to hear more stories about the people, research, and discoveries helping to shape the future of healthcare, subscribe to Behind the Genes on your favourite podcast app.  [00:30:45] Sharon: Thank you for listening. I've been your host, Sharon Jones. Behind the Genes is produced by Deanna Barac, Florence Cornish, Sophie McLachlan, and Katie Revell at Bespoken Media. 

Three cases sitting in front of three different systems. None of those systems have delivered what was promised.Nolan Wells was an eighteen-year-old who went to a boat party on Horn Island, Mississippi, and was the only one who did not come home. The state performed an autopsy and retained his throat. The trachea, hyoid bone, and laryngeal cartilage. Nineteen days later, no results released. The family's independent autopsy came back undetermined. A grand jury referral is pending.Nancy Guthrie has been missing from her Tucson home for close to six months with no arrest and no suspect named. On the same day in July, three FBI sources gave three contradictory answers about the ransom notes. A retired FBI agent told a national audience the case is cold. Genetic genealogy testing on DNA from her home started five months ago with no public update.Lindsay Clancy's jury is seated. Both sides agree she killed her three children. She was prescribed thirteen psychiatric medications in four months. After the children died, she was intubated in a hospital bed and wrote a single question on a whiteboard. The prosecution reads it as guilt. The defense reads it as confusion.A grand jury with subpoena power is pending in Mississippi. Three FBI sources in Arizona cannot agree on the nature of their own central evidence. A medical system in Massachusetts prescribed thirteen drugs, ignored a husband saying his wife had turned into a zombie, and the state now wants to prove that patient was sane beyond a reasonable doubt. None of these institutions delivered what they were built to deliver.Retired FBI Special Agent Jennifer Coffindaffer examines all three cases, the systems behind each, what connects their failures, and why none of them have produced the answers these families need.Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/ Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1 Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/TrueCrimePodThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.#NolanWells #NancyGuthrie #LindsayClancy #HiddenKillers #TrueCrime #JenniferCoffindaffer #FBI #GrandJury #InsanityDefense #PostpartumPsychosis

Father Nicanor Austriaco, a molecular biologist and Dominican Catholic priest, joins Trending with Timmerie: Episode Guide When should men be dating? (2:26) Uterine transplant – womb transplants to fix infertility? (19:15) Tuesday on Trending (38:42) Genetic engineering – "deextinction" of extinct species (39:45) Resources mentioned: Episode on the human experiment of surrogacy and IVF https://relevantradio.com/2026/07/st-mary-magdalene/ Transplanting the Womb: A Catholic Bioethical Analysis https://www.ncbcenter.org/store/transplanting-the-womb-a-catholic-bioethical-analysis

Three families asked the system for something basic. Answers. Protection. Help. None of them received it.Nolan Wells was eighteen. He went to a boat party on Horn Island, Mississippi, and was the only one of the group who did not come home. The state retained his throat during the first autopsy. Nineteen days later, no findings released. The independent autopsy returned undetermined. A grand jury is pending.Nancy Guthrie has been missing from Tucson for nearly six months. Three FBI sources gave three different answers about the ransom notes on the same day. A former FBI agent called the case cold on camera. Genetic genealogy testing began in February. Five months later, nothing.Lindsay Clancy's jury is seated in Plymouth Superior Court. Both sides agree she killed her three children. She was prescribed thirteen psychiatric medications in four months. Her husband told the doctors she had become a zombie. After the children died, intubated and unable to speak, she wrote a single question on a whiteboard. The prosecution and defense cannot agree on what that question means.A grand jury with subpoena power. An FBI that cannot agree on its own evidence. A medical system that prescribed thirteen drugs, ignored the husband's warnings, and now wants to prosecute the patient it failed. The institutions in each of these cases had one job and none of them did it.The grand jury can subpoena testimony under oath. The genetic genealogy lab has had DNA for five months and said nothing. The medical system that prescribed thirteen drugs and ignored the husband's warnings is now the same system the prosecution needs to prove produced a sane patient. Each institution had one responsibility and none of them fulfilled it.Retired FBI Special Agent Jennifer Coffindaffer examines all three cases, the thread connecting them, what the grand jury and the trial and the investigation should produce, and what the institutions handling each one owe to the families who are still waiting.Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/ Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1 Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/TrueCrimePodThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.#NolanWells #NancyGuthrie #LindsayClancy #HiddenKillers #TrueCrime #JenniferCoffindaffer #FBI #GrandJury #InsanityDefense #PostpartumPsychosis

In this episode Garth and special guest host Jane Halonen interview Nancy Segal from California State University, Fullerton in Fullerton, CA. Nancy discusses her lifelong twin research, books, and current projects. She describes how an undergraduate essay sparked her career, her work with the Minnesota twins reared-apart study, and how behavioral genetics became more accepted as evidence accumulated. She previews her trade book Twinship: What Twins' Ties Reveal About Relationships and notes she has nine published books, including work on Auschwitz twins, switched-at-birth Colombian identical twins, and a case involving gay fathers and twin sons. Nancy discusses twin-loss research, expert-witness cases, and doppelgangers used to counter "treated alike" critiques. She explains rising twinning rates (delayed childbirth, IVF), emphasizes twin studies' relevance to everyone, rejects evidence for "twin telepathy," and invites participation via her website and twin study center. [Note. Portions of the show notes were generated with Descript AI.]

See more at>>>  https://theserapeum.com/his-story-the-seed-war/ Bitchute – Where We Don't Have To Watch Our Mouths!Click Here For Exclusive Deal and Remove all ads and secure your privacy!https://www.bitchute.com/affiliate/dustinnemosIf you appreciate the work we do and wish to support us, you can donate here >> https://www.nemosnewsnetwork.com/donateCarbonShield60 Oil Infusions 15%OFF!Go to >> https://www.redpillliving.com/NemosCoupon Code: NEMOSSleepy Joe Sleep Aidhttps://redpillliving.com/sleep

“Is transhumanism a sin?” This question opens a discussion on the ethical implications of modern technology, including insights from the AI encyclical. The conversation also addresses whether IVF remains problematic, the Church’s stance on genetic engineering, and the complexities of recognizing AI as a unique life. Join the Catholic Answers Live Club Newsletter Invite our apologists to speak at your parish! Visit Catholicanswersspeakers.com Questions Covered: 05:30 – What is the main takeaway about transhumanism/ posthumanism from the AI encyclical. 16:00 – Is IVF still bad? 23:10 – Anthropology proves we come from apes. I don’t believe in Adam and Eve. How do you explain that? 34:28 – What does the Church say about genetic engineering and implants? 41:38 – At what level of advancement would the Church recognize AI as an individual unique life and baptize it? 45:28 – If a woman is able to undergo a procedure where she has her eggs frozen and later reimplanted without any damage to them or her, would this be ethical? 51:59 – Should we throw out the idea of humans coming from apes since we haven’t found any intermediate step between us and them?

Three different FBI sources. Three different answers. On the same day. About the single most important piece of evidence in the Nancy Guthrie kidnapping.Reuters said all the ransom notes are fabricated. The Phoenix field office said some may be legitimate. TMZ's sources said the original two are more credible than not. The Bureau cannot agree internally on whether the central evidence in its own active case is real or manufactured.Nancy Guthrie has been missing from her Tucson home for nearly six months. No suspect identified. No arrest. Former FBI agent Steve Moore went on camera and said what no official source has admitted. The case is completely cold. He told Brian Entin that fresh agents will eventually rotate in because the current investigators are stuck.This case has attracted cons alongside its genuine investigation. Derrick Callella pleaded guilty to posing as a kidnapper and sending fake ransom messages directly to Nancy's family while the real kidnapping was still open. Someone else separately sent TMZ a dozen emails demanding Bitcoin for information. The resources devoted to sorting real leads from manufactured noise have been enormous.Genetic genealogy testing began in February using DNA recovered from inside the house. That was five months ago. The enhanced photo of the masked figure on Nancy's porch has never been publicly released.Nancy's face is on the billboards across Tucson. The suspect's is not. The enhanced photo of the masked figure was captured on her porch camera. It has never been made public. These are deliberate decisions by the people running this investigation, and no one has explained the logic behind any of them.Retired FBI Special Agent Jennifer Coffindaffer joins Hidden Killers to examine the Bureau's contradictions, what happens mechanically when a case goes cold, whether the genetic genealogy testing has produced results that have not been shared, and whether investigators already know more about porch guy than they have told the public.Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/ Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1 Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/TrueCrimePodThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.#NancyGuthrie #FBI #HiddenKillers #TrueCrime #JenniferCoffindaffer #Tucson #PorchGuy #RansomNotes #PimaCounty #ColdCase

Watch every episode ad-free & uncensored on Patreon: https://patreon.com/dannyjones Ido Portal is the world's foremost expert on human movement. Ido has spent a lifetime studying, combining and evolving elements from an enormous range of martial arts, dance genres, athletic endeavors and science to develop a unified theory and practice of movement called “The Ido Portal Method.” https://www.idoportal.com SPONSORS https://whiterabbitenergy.com/?ref=DJP - Use code DJP for 20% off. EPISODE LINKS https://www.instagram.com/portal.ido https://www.idoportal.com FOLLOW DANNY JONES https://www.instagram.com/dannyjones https://twitter.com/jonesdanny OUTLINE 00:00 - The millionaire athlete approach to wellness 04:47 - Freshness & removing the mask of athletes 08:29 - Downside of "flow state" 17:43 - "World champions are robots" 22:06 - Become a practitioner 28:17 - You need to de-ambition yourself 30:41 - Why Ido makes Christian McCaffrey read & do math 38:36 - The spiritual journey of pro athletes 41:43 - Daily strength & conditioning practices 47:17 - Peripheral vision training 55:58 - Genetic ability vs. trained ability 01:04:22 - Doing what you suck at 01:13:27 - The state of mind of a practitioner 01:17:01 - Breathwork is oversimplified 01:25:57 - Movement design for Bollywood movies 01:28:34 - Indonesian "trance states" without drugs 01:35:44 - Psychological effects of desert training 01:38:02 - The Yoga lie 01:40:40 - Surfing vs. skateboarding vs. sports 01:45:59 - Why you shouldn't stretch 01:53:05 - The power of self-observation 02:01:34 - The active hanging challenge 02:06:31 - PEDs & the Enhanced Games 02:13:25 - Ido's view on supplements 02:16:31 - Suffering consciously 02:21:11 - Meditation has been distorted Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dan Sullivan and Peter Diamandis discuss human enhancement, biotechnology, and entrepreneurship. Peter shares insights from the Enhanced Games in Las Vegas, where performance-enhanced athletes set just one world record, alongside ethical debates on embryo sequencing for IVF trait selection. They explore gene therapies, biohacking for muscle and cognitive gains, and AI’s power to enable solo founders, even those over 70, with leaner, lower-cost ventures. In this episode: Insights into the Enhanced Games where athletes used performance-enhancing drugs, and the ethical implications of genetic selection in IVF. Discover the latest advancements in gene therapies aimed at increasing muscle mass and cognitive abilities, and the societal pushback against these innovations. Explore the potential for a new educational system that fosters entrepreneurial spirit in students and the advancements in biotechnology aimed at extending human lifespan.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In episode 171, “Fragile X Syndrome Day: Clinical Challenges, Care Strategies, and Emerging Therapies,” Craig A. Erickson, MD, professor of psychiatry at Cincinnati Children's Hospital, discussed the evolving landscape of Fragile X syndrome (FXS) care in honor of National Fragile X Syndrome Day. Erickson reviewed current challenges in recognizing and diagnosing FXS. He also underscored the importance of genetic testing and outlined key counseling points for families once a diagnosis is confirmed.Erickson, who also serves as the director of the Cincinnati Fragile X Research and Treatment Center, provided an overview of behavioral and neuropsychiatric management across the lifespan. He highlighted evidence-informed approaches for ADHD, irritability and aggression, and anxiety, as well as the critical role of early intervention and structured supports in adulthood. The discussion closed with a look at emerging therapeutics and how these advances may reshape clinical practice and long-term outcomes for individuals with FXS.Looking for more Genetic Disorders discussion? Check out the NeurologyLive® Genetic Disorders clinical focus page.Episode Breakdown: 1:25 – Challenges in recognizing and diagnosing Fragile X  3:25 – Genetic counseling and cascade testing after diagnosis  6:00 – Managing behavioral and neuropsychiatric symptoms  9:55 – News Minute  12:45 – Clinical management across the lifespan  17:12 – Emerging therapies and research priorities  21:17 – Why Fragile X awareness remains critical  The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date FDA Accepts NDA for Apnimed's AD109 for the Treatment of Obstructive Sleep Apnea FDA Accepts NDA for Axsome Therapeutics' AXS-12 for the Treatment of Cataplexy in Narcolepsy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

On the Sioux Nation Podcast today, we are doubling down on deworming practices. The process of deworming livestock can be traced to the 1800's. Yet new findings presented by Dr. Joe Dedrickson of Huvepharma are showing the positive results of doubling up to improve efficacy and avoid resistance.

CardioNerds (Drs. Apoorva Gangavelli, Jenna Skowronski, and Hannah Every) discuss the continuum of prevention and heart failure with Drs. Anu Lala and Martha Gulati. Grounded in a clinical case of a 55-year-old woman with uncontrolled hypertension, type 2 diabetes, and obesity who is on the trajectory toward heart failure, this episode unpacks a paradigm-shifting framework from a joint HFSA/ASPC Scientific Statement. The discussion explores how prevention should not be siloed from heart failure management but rather integrated across a patient’s lifespan—from primary prevention in at-risk individuals, to secondary prevention in those with established heart failure, to tertiary prevention in patients with advanced therapies such as LVADs and heart transplantation. The experts highlight the importance of aggressive risk factor management, biomarker-guided screening, the AHA’s Life’s Essential 8, and the need for multidisciplinary collaboration and systems-level change to shift heart failure care from reactive to proactive. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Systemic inflammatory diseases are associated with an elevated CVD risk that has significant implications for early detection, risk Heart failure prevention is a continuum, not a checkpoint. Prevention applies at every stage—from at-risk (Stage A) through advanced/post-transplant care—and every clinical encounter is an opportunity to intervene. The AHA’s Life’s Essential 8 (diet, physical activity, nicotine exposure, sleep, BMI, blood lipids, blood glucose, blood pressure) forms the foundation at every stage. Hypertension carries the highest population-attributable risk for heart failure of any modifiable risk factor. In the Framingham Heart Study, 91% of patients with newly diagnosed HF had pre-existing hypertension. The SPRINT trial demonstrated a 38% reduction in HF incidence with intensive blood pressure targets (30 ng/L or NT-proBNP >125 ng/L) identify individuals at heightened risk for progression to symptomatic HF. The ACC/AHA/HFSA guidelines give a Class IIa recommendation for natriuretic peptide screening in at-risk patients. Urine albumin-to-creatinine ratio (UACR) is an underutilized screening tool that provides additional insight into CKM risk. The heart failure label does not close the prevention window—it accentuates it. Secondary prevention through GDMT optimization (quadruple therapy in HFrEF) and continued risk factor management remains critical. Tertiary prevention extends to post-LVAD and post-transplant patients, where hypertension, diabetes, obesity, and CKD management remain essential to long-term outcomes. Show notes For a comprehensive review, please review the full HFSA/ASPC Joint Scientific Statement: Lala A, Beavers C, Blumer V, et al. The Continuum of Prevention and Heart Failure in Cardiovascular Medicine. J Card Fail. 2026;32:75-105. doi:10.1016/j.cardfail.2025.06.013 1. What is the “continuum of prevention” framework, and how does it differ from traditional approaches to heart failure prevention? Historically, prevention and heart failure management have been treated as separate disciplines—primary prevention handled by preventive cardiologists and treatment managed by heart failure specialists. This joint HFSA/ASPC Scientific Statement reframes prevention as a dynamic, continuous process that spans a patient’s entire lifespan, regardless of HF stage or ejection fraction. The framework maps onto the ACC/AHA HF staging system: Primary prevention targets Stage A (“at risk”) and Stage B (“pre-HF”) patients to reduce the burden of incident HF. Secondary prevention targets Stage C (symptomatic) and Stage D (advanced) patients to reduce the impact of established HF through GDMT optimization and ongoing risk factor management. Tertiary prevention encompasses risk factor management in patients with LVADs or heart transplants—populations where hypertension, diabetes, and obesity still drive outcomes. The Central Figure of the statement illustrates that Life’s Essential 8 (blood pressure and lipid control, diabetes management, exercise, sleep, smoking cessation, weight management, and diet/nutrition counseling) forms the foundation at every stage, with pharmacologic and device-based therapies layered on top as disease progresses (Figure) 2. How do traditional risk factors drive heart failure, and what should clinicians prioritize? Hypertension carries the greatest population-attributable risk for HF. In the Framingham Heart Study (N=5,143), HTN was associated with a 2- to 3-fold increased risk of HF, with a population-attributable risk of 39% in men and 59% in women. The SPRINT trial showed a 38% reduction in HF incidence and 25% reduction in the primary composite outcome with intensive BP targets (30 ng/L or NT-proBNP >125 ng/L) are associated with heightened risk for progression to symptomatic HF. In the ARIC study, incorporating NT-proBNP reclassified 20% of older adults without HF into Stage B. Factors that affect interpretation include age, sex, obesity (lower values), and CKD (higher values). High-sensitivity cardiac troponin (hs-cTn): Concentrations above the 99th percentile are now included in the definition of Stage B HF. Troponin testing may complement natriuretic peptides, particularly when BNP/NT-proBNP values are ambiguous. Risk scores: The PCP-HF equation predicts 10-year HF risk using traditional risk factors plus QRS duration. The AHA PREVENT score incorporates HF risk calculation and includes markers of kidney function (albuminuria, eGFR), though it may underestimate risk in men and Black adults. The CKM syndrome staging framework (Stages 0–4) provides a holistic approach to assessing systemic cardiovascular-kidney-metabolic risk. 4. What are the key nontraditional risk factors and cross-cutting themes in heart failure prevention? Genetics: Pathogenic cardiomyopathy variants exist in ~1 in 200 individuals in the general population. The HFSA and ACMG recommend cascade testing to identify at-risk family members. Polygenic risk scores for dilated cardiomyopathy show a 3.8-fold risk for DCM in the top 10th percentile compared with the median. Sex-specific considerations: Women have 2.8 times the odds of developing HFpEF, while men have similarly increased odds of HFrEF. A complete obstetric/gynecologic history is essential—preeclampsia is associated with a 4-fold increased risk of HF. Peripartum cardiomyopathy requires intentional screening in high-risk populations. Cardiotoxic exposures: Clinicians should be aware of medications that cause direct myocardial toxicity (e.g., anthracyclines, trastuzumab, tyrosine kinase inhibitors). A team-based approach with pharmacists can help optimize medication selection and risk factor modification. Social determinants of health: Environmental exposures (air pollution, arsenic, lead, cadmium), food insecurity, financial instability, and limited healthcare access contribute to HF risk and progression. Equity-focused, risk-based prevention strategies are needed. Psychological health: Depression is common in HF and independently associated with worse outcomes. Screening with brief questionnaires (e.g., PHQ-2) is recommended. Meditation, spirituality, and holistic wellness approaches remain underutilized. 5. What systems-level and policy changes are needed to move the needle on heart failure prevention? Multidisciplinary HF prevention clinics that bring together preventive cardiologists, HF specialists, endocrinologists, nephrologists, dietitians, pharmacists, exercise physiologists, and genetic counselors are advocated by the statement. EHR-embedded risk stratification could proactively flag patients on a trajectory toward HF—analogous to sepsis alerts or fall risk flags—enabling earlier intervention, particularly for patients who may not reach a cardiologist. Cardiac rehabilitation remains underutilized, particularly in HFrEF (Class 2b recommendation) and HFpEF (not yet covered by Medicare). The HF-ACTION trial showed quality-of-life benefits, and the REHAB-HF trial showed particular benefit in older patients with HFpEF. Policy priorities include expanding insurance coverage for preventive screening and novel therapies (SGLT2i, GLP-1 RAs, nsMRAs), reducing clinical inertia through team-based care models with closer follow-up intervals, and ensuring equitable access to evidence-based therapies across diverse populations. Digital health and AI hold promise for personalized risk prediction, remote monitoring (e.g., wearable devices, implantable PA pressure monitors), and virtual cardiac rehabilitation to overcome access barriers. Figure  Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013) References Key references are bolded. Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013 Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146(5):e18-e43. doi:10.1161/CIR.0000000000001078 SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939 Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557-1562. doi:10.1001/jama.1996.03530440037034 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997. doi:10.1001/jama.288.23.2981 Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153. doi:10.1056/NEJM200001203420301 Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720 Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286 Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145(6):437-447. doi:10.1161/CIRCULATIONAHA.121.057983 Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773-786. doi:10.1016/S0140-6736(24)01498-3  Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963 Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636-1664. doi:10.1161/CIR.0000000000001175 Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149(6):430-449. doi:10.1161/CIRCULATIONAHA.123.067626 Khan SS, Ning H, Shah SJ, et al. 10-year risk equations for incident heart failure in the general population. J Am Coll Cardiol. 2019;73(19):2388-2397. doi:10.1016/j.jacc.2019.02.057 Bozkurt B, Fonarow GC, Goldberg LR, et al. Cardiac rehabilitation for patients with heart failure: JACC expert panel. J Am Coll Cardiol. 2021;77(11):1454-1469. doi:10.1016/j.jacc.2021.01.030 Packer M. Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation. 2018;137(15):1614-1631. doi:10.1161/CIRCULATIONAHA.117.032474 Lala A, Tayal U, Hamo CE, et al. Sex differences in heart failure. J Card Fail. 2022;28(3):477-498. doi:10.1016/j.cardfail.2021.10.006 Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure. Eur J Heart Fail. 2021;23(3):352-380. doi:10.1002/ejhf.2115 Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline. J Card Fail. 2018;24(5):281-302. doi:10.1016/j.cardfail.2018.03.004 Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological health, well-being, and the mind-heart-body connection: a scientific statement from the American Heart Association. Circulation. 2021;143(10):e763-e783. doi:10.1161/CIR.0000000000000947 Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet. 2022;399(10333):1391-1400. doi:10.1016/S0140-6736(22)00369-5

Award winning journalist, Amy Robach, joins SHE MD to share the powerful story behind her breast cancer diagnosis, from discovering her cancer during a routine mammogram on live television to navigating the emotional and physical challenges that followed. Amy opens up about the shock of hearing the words “you have cancer,” the decisions she faced throughout treatment, and how her experience transformed the way she approaches her health and advocacy.Together, Dr. Thaïs Aliabadi and Mary Alice Haney dive into the importance of understanding your personal breast cancer risk, why family history is only one part of the equation, and how advancements in screening and prevention can help women take a more proactive role in their health. Amy shares why she believes early detection saved her life and why every woman should feel empowered to ask questions, know their body, and advocate for the care they deserve.In this episode, Amy, Dr. Aliabadi, and Mary Alice discuss breast cancer awareness, mammogram recommendations, genetic risk factors, the emotional journey of diagnosis, and the importance of becoming your own strongest health advocate.Subscribe to SHE MD Podcast for expert tips on PMOS, endometriosis, fertility, hormonal balance, mental health, and more. Share with friends and visit SHE MD website and Ovii for research-backed resources, holistic health strategies, and expert guidance on women's health and well-being.SponsorsNovartis: For more information, visit BreastCancerUnscripted.comWhat You'll LearnHow Amy Robach's live TV mammogram led to an unexpected breast cancer diagnosisWhy most women diagnosed with breast cancer do not have a family historyThe importance of understanding your personal lifetime breast cancer riskHow breast density influences screening recommendationsWhen women may need screening earlier than age 40The role of genetic testing in identifying inherited cancer riskHow early detection can improve treatment options and outcomesThe emotional and mental health challenges that continue long after diagnosisKey Timestamps00:00 How A Live TV Mammogram Saved Amy Robach's Life01:45 Amy Robach Opens Up About Her Breast Cancer Diagnosis02:01 Why Amy Never Thought Cancer Could Happen To Her03:54 What Robin Roberts Said That Changed Everything05:47 The Moment Amy Found Out Her Results Were Suspicious07:44 Why Amy Waited 30 Days To Go Back For More Imaging08:47 The Lump She Never Felt And The Biopsy That Followed09:01 Hearing The Words Your Cancer Is Malignant12:13 The Second Tumor Nobody Expected To Find15:01 How Breast Cancer Affected Her Plans To Have Children16:10 Why Early Detection Is The Most Powerful Tool Women Have17:03 The Biggest Misconceptions Women Have About Breast Cancer18:06 How A Cancer Diagnosis Changes You Forever20:37 Why Women Feel Alone After A Breast Cancer Diagnosis23:06 Understanding Your Oncotype Score And Risk Of Recurrence25:42 Why Sharing Your Story Can Save Someone Else's Life28:34 Life After A Double Mastectomy, The New Normal29:15 How Breast Cancer Made Amy A Stronger Version Of HerselfKey TakeawaysBreast cancer can affect women with no family history or known genetic mutation.Knowing your personal risk is just as important as following age based screening guidelines.Dense breast tissue can increase breast cancer risk and may require additional imaging.Early detection offers more treatment options and can improve outcomes.Genetic testing may be appropriate for women with a family history of breast, ovarian, or pancreatic cancer.Sharing personal stories can empower more women to prioritize screening and advocate for their health.Guest Bio: Amy RobachAmy Robach is an Emmy Award winning journalist, bestselling author, and longtime television anchor known for her work on Good Morning America, 20/20, and the Today Show. In 2013, while undergoing a mammogram on live television to encourage women to get screened, she was diagnosed with stage II breast cancer. Since then, Amy has become a passionate advocate for breast cancer awareness, early detection, and patient education. Through her storytelling and advocacy, including her work with the Breast Cancer Unscripted campaign, she continues to empower women to understand their risk, prioritize screening, and find strength through community.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this episode of *Good Day Health*, host Doug Stephan is joined by Dr. Ken Kronhaus for a discussion of the latest medical research and practical strategies for improving long-term health. The conversation explores the importance of making informed decisions about dietary supplements, including the potential risks of excessive niacin intake and why consumers should understand both the benefits and possible side effects of vitamins and nutritional products before adding them to their daily routines.Dr. Ken also highlights the many health benefits of regular exercise, discussing its role in supporting mental health, strengthening the immune system, and reducing the risk of illness, including research examining its relationship to COVID-19 outcomes. The episode takes a closer look at advances in genetic testing and personalized medicine, explaining how genetic screening is helping identify individual risks for common diseases and allowing for more targeted prevention and treatment strategies.Doug and Dr. Ken also emphasize the importance of building trusted relationships with qualified healthcare providers and making evidence-based decisions about medical care. The discussion explores how nutrition, diet, and appropriate supplement use can influence cardiovascular health and overall wellness, while reinforcing the value of healthy lifestyle habits as the foundation for disease prevention.Throughout the episode, listeners gain practical insights into the latest medical advancements and learn how thoughtful choices about exercise, nutrition, preventive care, and personalized medicine can contribute to better health and a higher quality of life. For more on Good Day Health…Website: GoodDayHealthShow.comSocial Media: @GoodDayNetworks

Well guys, it's been a heck of a week - apologies for getting this out somewhat late, my brain is *egg of frying pan sound.* I know you all can understand. Be prepared! I learn some neuroscience and immunology today because it's a ~fully body~ Schauer this week, ayo! I'd like to thank my parents for bestowing me with a last name rife with self-branding related puns. I appreciate you all! Chat next week! Books: A Silent Fire: The Story of Inflammation, Diet & Disease - Shilpa Ravella (Transplant Gastroenterologist) Most Delicious Poison: The Story of Nature's Toxins - from Spices to Vices - Noah Whiteman (Evolutionary Biologist) The Human Brain Book: A Visual Guide to Structure & Function - Rita Carter (Science & Medicine Writer) Behave: The Biology of Humans at Our Best and Worst - Robert M. Sapolsky (Neuroscientist & Primatologist) Why We Sleep: Unlocking the Power of Sleep and Dreams - Matthew Walker, PhD (Prof. of Neuroscience & Psychology) An Elegant Defense: The Extraordinary New Science of the Immune System - Matt Richtel (Pulitzer Prize Winning Writer for NYT) Organ Speak: What It Really Means to Listen to Our Bodies - Guilia Enders (Physician, Microbiologist, Author) The Mind-Gut Connection: How the Hidden Conversations Within Our Bodies Impact Our Mood, Our Choices, and Our Overall Health - Emeran Mayer, MD (Gastroenterologist & Educator)  Clean: The New Science of Skin and the Beauty of Doing Less - James Hamblin, MD, MPH (Preventative Medicine Specialist) Believe it or not, I got most of my soap information from this book (I also used the ‘Natural saponins' link below) - it's mainly about hygiene and the cosmetic industry ripping everyone off but it did also teach me how to make soap.  Also, most of the sources from this episode are from the books I've read over the years, if there's information you can't find linked below, it has come from a book listed above. I put everyone's occupations to narrow down what book it's likely from.  Online Sources: Good News - Attorney General James Sues Some of Nation's Largest Chemical Companies Over Toxic Pollution from Consumer Products https://ag.ny.gov/press-release/2026/attorney-general-james-sues-some-nations-largest-chemical-companies-over-toxic Researchers discover the eye's hidden cleanup system https://medicalxpress.com/news/2026-07-eye-hidden-cleanup.html Macrophages in the artery wall ‘smell' their surroundings https://www.lji.org/news-events/news/post/macrophages-in-the-artery-wall-smell-their-surroundings/ Cells That ‘Taste' Danger Set Off Immune Responses https://www.quantamagazine.org/tuft-cells-that-taste-danger-set-off-immune-responses-20191115/ Natural saponins and macrophage polarization: Mechanistic insights and therapeutic perspectives in disease management https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1584035/full Inflammation Forces Brain Stem Cells to Halt Neurogenesis https://neurosciencenews.com/inflammation-neurogenesis-31011/ Inhaling high-dose CO2 clears Alzheimer's proteins from the brain https://www.newscientist.com/article/2580471-inhaling-high-dose-co2-clears-alzheimers-proteins-from-the-brain/ Genetic variation across the human olfactory receptor repertoire alters odor perception https://www.pnas.org/doi/10.1073/pnas.1804106115  Comparative Toxicogenomics Database https://ctdbase.org/ This is just the think to the genetics database I've been using, for all the genes I mention just type them into the search and *voila*  Free Newspaper Archive: UCR | California Digital Newspaper Collection  https://cdnc.ucr.edu/ Learn more about your ad choices. Visit podcastchoices.com/adchoices

Animals have a genetic switch that puts them in winter mode Study reveals a winter version of the biological clock Contact the Show: coolstuffdailypodcast@gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Further reading: New species of extinct vampire-squid-like cephalopod When teeth grow on the body Fossil shark turns into mystery pterosaur Scientists Had Never Seen This Elusive Whale Alive—Until Now Show transcript: Welcome to Strange Animals Podcast. I'm your host, Kate Shaw. This month I wasn't sure what to cover in this episode, so I decided to just click on four random bookmarks of scientific articles that I've had waiting for attention, and we'll discuss them. We haven't done a four articles episode in a long time! The first article is from March 2022, and it's about the discovery of an ancient cephalopod. Cephalopods include octopuses and squid. Octopuses famously have eight arms, while squid have eight arms and two feeding tentacles. Despite its name, the deep-sea vampire squid is actually more closely related to octopuses than to squid, and a newly discovered fossil is an ancestor to both. The fossil is 328 million years old and was discovered in Montana, in the United States, in 1988 but was only studied recently. Fossils of soft-bodied animals are incredibly rare, and this one is remarkably well-preserved. All of the animal's arms are preserved, including the suckers, but instead of eight arms, it had ten. Scientists have long suspected that the ancestors of modern octopuses and vampire squid had ten arms. The vampire squid has eight arms and two feeding filaments that are vestigial arms. But this is the first fossil found that shows ten arms. The fossil is of an animal with a torpedo-like body shaped like a modern squid. Two of its arms appear to be elongated compared to its other arms. It's about 4 and a half inches long including its arms, or 12 cm. That's pretty much all we know about it now, but hopefully the fossil will reveal more information as it continues to be studied. Our next article is from October 2017 and is intriguingly titled “When teeth grow on the body.” It sounds horrific, but it's actually a study of certain catfish that grow bony plates with tiny teeth on their bodies as defense. Catfish don't have scales, but some species of denticulate catfish that live in South America grow bony plates that act like armor. Many of these plates are covered in thin little teeth–actual teeth, including enamel and dentin, with pulp inside. They're called extra-oral teeth, dermal denticles, or odontodes, and the study determined that they appeared about 120 million years ago in ancient catfish that hadn't yet evolved the bony plates. The teeth regrow when they're lost, and in some species, males grow larger teeth than females and use them to fight other males. Imagine biting someone without needing to open your mouth. Our next article is from November 2020, about more fossils. The fossils were discovered in a collection at the Sedgwick Museum of Cambridge and the Booth Museum at Brighton in England, and were originally found in the latter half of the 19th century by miners. A PhD student at the University of Portsmouth was studying fossilized shark spines from the collection when he realized they weren't actually shark spines. Instead, they were jaw fragments from pterosaurs. Pterosaurs were flying reptiles that filled many ecological niches that birds fill today. One of the species identified from the collection is called Ornithostoma, which means bird mouth, an animal that lived in the early Cretaceous, about 110 million years ago, in what is now Europe. We know very little about it except that it didn't have teeth, but it probably ate fish. But there were some other jaw fragments that didn't belong to Ornithostoma, and in fact don't match up to any known pterosaur jaws. It may belong to a new species, but the fossils are so fragmentary that there's no way to know for sure. The rocks that the fossils came from were completely destroyed more than a century ago during phosphate mining, so unless more fragments are found in other collections, we may never learn more about this mystery pterosaur. Our last article is from July 2022, and I have no idea why I haven't talked about it on the podcast before now. It's about Sato's beaked whale, also called kurotsuchi. It's a type of four-toothed whale with a short beak, and it's dark gray and can grow up to 23 feet long, or 7 meters. It was only identified in 2016 as being different from the two other known species of four-toothed whales, after careful analysis, including DNA analysis, of dead individuals that had been found washed ashore. Until the summer of 2021, no one had ever seen a living Sato's beaked whale. Then some researchers studying orcas spotted 14 of the beaked whales swimming together between Hokkaido, Japan and the Kuril Islands. The scientists recognized that these were unusual whales and they were able to get a small skin sample from one. Genetic testing confirmed that they were indeed Sato's beaked whales. Researchers think the whales may spend at least part of the year in tropical waters, since that's where cookie cutter sharks live and the whales show circular bite scars from cookie cutter sharks. Not much is known about most species of beaked whale, and Sato's beaked whale is especially mysterious. But at least we know it's alive and well right now. Thanks for your support, and thanks for listening!

Send us Fan Mail Support the showSponsor Affiliates Empowering Your Healthhttps://www.atecam.com/Get YOUR Own Joburg Protein Snacks Discount Code:  Damaris15 Or Damaris18Feeling need to Lose Weight & Become metabolically HealthyGET METABOLIC COURSE GLP 1 REseTThis course is designed for individuals looking to optimize their metabolic health through integrative and functional medicine approaches. Whether you're on a GLP-1 medication or seeking natural ways to enhance your metabolic function, this course provides actionable steps, expert insights, and a personalized roadmap sustainable wellness.Are you feeling stressed, tired, or Metabolism imbalanced? Take advantage of our free mindful steps to help improve your well-being.ENJOY ONE OF our Books Mindful Ways  Health Wealth & Life https://stan.store/MindfullyintegrativeJoin Yearly membership ALL IN ONE  FUNCTION HEALTHAsk Us for help with Medica...

Elizabeth Bruenig, staff writer at The Atlantic, discusses how the new data available on inherited maladies can save lives but can also complicate the decision people make about treatment. Photo: Female doctor sharing electronic test results with patient at clinic. Medical expert and woman are examining reports. They are sitting in examination room. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Download Chapter 1 of Breast Implants, Explant Surgery, and Breast Implant Illness — FREE → https://robert-whitfield-md-pllc.myklpages.com/l/ScrLbh In this episode, board-certified plastic surgeon Dr. Robert Whitfield joins the show to walk through his path from oncologic microsurgical reconstruction to a practice focused on implant removal (explant) surgery and holistic surgical recovery. Dr. Whitfield discusses his team's published research analyzing capsule tissue from hundreds of patients using PCR testing, and what that data shows about bacterial contamination rates compared to smaller prior studies. He explains how genetic variation in detox pathways — including methylation and glucuronidation — may influence how patients respond to surgical devices, and how his team uses this information as part of pre-surgical planning.

What happens when a deep-seated thirst for childhood revenge turns into a career in genetic engineering? You get an absolute badass who is plotting the ultimate downfall of the world's deadliest killer. Krystal is a Ugandan entomologist (aka a massive bug nerd) who has dedicated her life to taking down the mosquito. Growing up in Uganda, surviving malaria was basically a terrifying game of Russian roulette. Crystal shares the raw, heart-wrenching origin story that fueled her career: watching her little brother suffer through brutal, fever-induced seizures all night while her family simply couldn't afford the medication to treat him. Crystal completely schools Jeremie and Brian on what malaria actually does to the human body - and it is no joke. We're talking brain damage from cerebral malaria, "black water fever" (where your urine turns black from liver damage), and even gangrene that leads to amputations. We also dig into the wild fact that out of the 3,500 species of mosquitoes on Earth, only about four are the real assholes responsible for the vast majority of malaria transmission in Africa. This episode is a massive reality check about the devastating barriers to healthcare in the developing world, the literal life-saving impact of the Global Fund, and the badass science that might just eradicate this disease for good. Grab your bug spray and tune in.Follow Sickboy: Instagram: https://www.instagram.com/sickboypodcastTiktok: https://www.tiktok.com/@sickboypodcastDiscord: https://discord.gg/expeUDN

Surgery doesn't end when you leave the operating theatre. And in fact, it begins long before you step into the hospital. Dr Rob Whitfield is a surgeon intent on doing things differently for his patients aka doing things better. From informed consent, to holistic and personalized post-op care and removing toxic implants, he is setting a new standard. With AI, regenerative medicine, and direct-to-consumer biotechnology the future isn't just better surgery but smarter preparation and recovery.Dr. Robert Whitfield understands what you're going through. He has listened to thousands of patients describe the same experience: symptoms that don't add up, doctors who dismiss them, and a desperate search for someone who will take them seriously.As a board-certified plastic surgeon certified by the American Board of Plastic Surgery, Dr. Whitfield has published the largest PCR-tested explant capsule series in the world, presented at major medical conferences, and built a patient education library with over 26 million views. He created the SHARP Method specifically because standard surgical care wasn't enough for his patients.ContactWebsite - https://www.drrobertwhitfield.com Join us as we explore:The unappreciated risks of breast implants, breast implant illness and genuine informed consent.What Dr Whifield's has learnt removing implants and testing them, and his unique SHARP method. Genetic sequencing, AI, genomic supplementation and where the standard of care is heading, including surgical robots.MentionsScience - Dr Whitfield's research and publications, https://www.drrobertwhitfield.com/media/researchSupport the showFollow Steve's socials: Instagram | LinkedIn | YouTube | Facebook | Twitter | TikTokSupport the show on Patreon:As much as we love doing it, there are costs involved and any contribution will allow us to keep going and keep finding the best guests in the world to share their health expertise with you. I'd be grateful and feel so blessed by your support: https://www.patreon.com/MadeToThriveShowSend me a WhatsApp to +27 64 871 0308. Disclaimer: Please see the link for our disclaimer policy for all of our content: https://madetothrive.co.za/terms-and-conditions-and-privacy-policy/

What happens when a deep-seated thirst for childhood revenge turns into a career in genetic engineering? You get an absolute badass who is plotting the ultimate downfall of the world's deadliest killer. Krystal is a Ugandan entomologist (aka a massive bug nerd) who has dedicated her life to taking down the mosquito. Growing up in Uganda, surviving malaria was basically a terrifying game of Russian roulette. Crystal shares the raw, heart-wrenching origin story that fueled her career: watching her little brother suffer through brutal, fever-induced seizures all night while her family simply couldn't afford the medication to treat him. Crystal completely schools Jeremie and Brian on what malaria actually does to the human body - and it is no joke. We're talking brain damage from cerebral malaria, "black water fever" (where your urine turns black from liver damage), and even gangrene that leads to amputations. We also dig into the wild fact that out of the 3,500 species of mosquitoes on Earth, only about four are the real assholes responsible for the vast majority of malaria transmission in Africa. This episode is a massive reality check about the devastating barriers to healthcare in the developing world, the literal life-saving impact of the Global Fund, and the badass science that might just eradicate this disease for good. Grab your bug spray and tune in.Follow Sickboy: Instagram: https://www.instagram.com/sickboypodcastTiktok: https://www.tiktok.com/@sickboypodcastDiscord: https://discord.gg/expeUDN

The "man-moulders of the new age" vs. Imago Dei. __________ Partner with thousands of others in supporting The Colson Center by visiting colsoncenter.org/cornerstone.

All Home Care Matters and our host, Lance A. Slatton were honored to welcome Josh Bowie and Dr. Divyen Patel from Your Genetic Wellness as guests to the show.   About Naga V. Naidu, Ph.D., Lab Director at Your Genetic Wellness:   Dr. Naga V. Naidu is a PhD-trained toxicologist and laboratory leader with more than 10 years of experience in forensic and clinical diagnostic laboratories. He earned his PhD in Toxicology in Houston, Texas, following completion of his bachelor's degree in pharmacy in India. Early in his career, he served as Scientific Laboratory Director at a forensic toxicology laboratory and achieved board certification as a Toxicology Chemist through the National Registry of Certified Chemists (NRCC).   Dr. Naidu has held multiple leadership and technical roles across forensic and clinical diagnostic environments. He currently serves as a General and Technical Consultant Director for several Clinical Diagnostic Laboratories, where he provides oversight in laboratory operations, test development, validation, regulatory compliance, and quality systems management.   His expertise includes method development and validation of advanced analytical platforms used in toxicology, molecular diagnostics, and genetic testing. Dr. Naidu has experience reviewing and supporting genotype-based testing panels and translating molecular data into clinically meaningful wellness and risk-assessment frameworks.   In addition to his technical expertise, Dr. Naidu is highly experienced in laboratory compliance and regulatory standards, including CLIA, CAP, proficiency testing, and quality assurance systems. His multidisciplinary background allows him to bridge scientific rigor, clinical relevance, and regulatory integrity, ensuring high-quality, reliable genetic and diagnostic testing.   About Josh Bowie, SVP of Strategy & Insights at Your Genetic Wellness:   Josh Bowie is a creative strategist and systems thinker dedicated to solving the "Last Mile" problem in precision health. As the SVP of Strategy & Insights at Your Genetic Wellness, Josh serves as the Strategic Lead for the Results to Routines™ framework, a methodology designed to translate complex biological data into clear, actionable wellness pathways for everyday life.   Josh's approach is rooted in the belief that data is only as valuable as the habits it inspires. He moves beyond the traditional model of overwhelming, static health reports, focusing instead on Actionable Biology: a human-centric design where technology and clinical expertise intersect to create sustainable change. By synthesizing market signals with a unique perspective on consumer behavior, Josh ensures that Your Genetic Wellness functions as a "GPS for the Human Body," empowering individuals to navigate their health with confidence and clarity.   A vocal advocate for collaborative wellness, Josh emphasizes that the most successful health journeys are never walked alone. His work focuses on building the bridges between cutting-edge science and the real-world decisions that define long-term vitality, ensuring the future of health is both personalized and profoundly practical.   About Your Genetic Wellness:   Your Genetic Wellness is shifting the conversation from reactive care to proactive clarity. Too often, we wait until symptoms appear before investigating our health, forcing us into a cycle of trial and error to find relief.   We believe in a different approach: providing a personal biological roadmap before the guesswork begins. Using a simple at-home swab, we translate unique genetic markers into clear, actionable insights that show how a body may process nutrients, respond to medications, and manage long-term wellness.   Whether you are a proactive professional, a parent, or a caregiver, we provide the data-driven confidence to move away from reactive "sick care" and toward more informed, personalized health decisions.

How can OBGYNs navigate the complexities of modern prenatal carrier screening? In this episode of BackTable Women's Health, host Dr. Nicole Faulkner interviews Dr. Mary Kate LoPiccolo, a pediatrician and medical geneticist at Mount Sinai, to break down the essentials of prenatal carrier screening in OBGYN practice. They discuss what carrier screening is, when to order it, and how to manage and interpret results in real-world clinical settings. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction 03:03 - Understanding Carrier Screening04:40 - Partner Testing: When and Why06:22 - Selecting the Right Panel Size08:27 - Managing Time Constraints and Making Referrals 10:52 - Pretest Counseling Essentials16:44 - Decoding Results and Effective Reporting 20:52 - Limits of OB Counseling26:19 - Navigating Common X-Linked Pitfalls 30:11 - Equity, Costs, and Over-Testing36:11 - Tele-Genetics and Lab Resources43:43 - Final Takeaways --- More about this episode Dr. LoPiccolo reviews the evolution from Tay-Sachs screening in Ashkenazi Jewish populations to today's pan-ethnic expanded panels, emphasizing carrier screening as a blood-based screening test for recessive and X-linked conditions ideally performed preconception and for both partners. The conversation covers panel size selection, best practices for pre-test counseling, common pitfalls with X-linked results, documentation and report interpretation, cost and equity barriers, and the value of referrals, telegenetics, lab genetic counselors, and resources like GeneReviews to optimize care. --- Resources GeneReviews - https://www.ncbi.nlm.nih.gov/books/NBK1116/ Open Evidence - https://www.openevidence.com/ --- BackTable Women's Health is the go-to podcast for gynecologists, gynecologic surgeons, and other healthcare professionals focused on women's health. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Following the release of Version 1.2026 of the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, Esophageal, and Gastric on June 16, 2026, the CGA-IGC Education Committee is pleased to present a special podcast episode exploring several of the key updates.In this episode, host Josie Baker, MS, LGC, speaks with NCCN Guideline Panel chair  Samir Gupta, MD; and members Jennifer Weiss, MD, MS; and Rachel Hodan, MS, CGC about key updates in Version 1.2026 of the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, Esophageal, and Gastric Cancer.Together they discuss expanded multigene panel testing recommendations for individuals with colorectal, gastric, and endometrial cancers, including the Category 2B designation for colorectal and gastric cancers diagnosed at age 50 or older. They also address the evidence behind broader testing, access challenges, and the need for more flexible care pathways.Additional topics include updated EPCAM-associated Lynch syndrome risks, limitations of salpingectomy alone for ovarian cancer risk reduction, the omission of PMS2 from the minimum gastric cancer panel, and the distinction between genetic evaluation and genetic testing for patients with multiple adenomas. The episode also introduces a new section on hereditary esophageal squamous cell carcinoma.

Dr. Doug explores the role of genetics in osteoporosis and emphasizes the power of lifestyle choices in influencing bone health. Challenging the notion that genetics predetermine bone outcomes, he highlights research showing the impact of environment, nutrition, and exercise.Study Linkshttps://pubmed.ncbi.nlm.nih.gov/18319743/https://pubmed.ncbi.nlm.nih.gov/16157825/https://www.nature.com/articles/s41588-018-0302-xhttps://pubmed.ncbi.nlm.nih.gov/28975661/https://pubmed.ncbi.nlm.nih.gov/41078374/https://pubmed.ncbi.nlm.nih.gov/14519707/https://pubmed.ncbi.nlm.nih.gov/15082697/https://pubmed.ncbi.nlm.nih.gov/15653003/https://pubmed.ncbi.nlm.nih.gov/21142350/

  Meg and Carrie are back for a fired-up part two on the topic that got them riled up last episode: compulsive lying.   In this candid Got HER Back Monday conversation, the hosts break down the difference between harmless white lies and the dangerous, manipulative kind: the pathological liars who are so charming and "godly" on the surface that no one questions them, until you've already lived a lie for years. They dig into where compulsive lying comes from (learned behavior, childhood chaos, or genetics), the real-world stakes of lying in a court of law, and the red flags to watch for in dating, from secret double lives to mysteriously replaced cell phones.   Plus, the receipts: why Carrie has never deleted a text since 2005 and what 94,000 screenshots can do for your peace of mind. If gaslighting has ever made you question your own reality, this honest, funny episode is your reminder to stand on the facts — and to leave the liars behind in 2026.   Chapters: 0:00 Cold Open: Standing on Facts 0:35 Got Her Back Monday & a Birthday Shoutout 1:30 Southern Comfort Food (and Cason's Review) 3:40 Why We Needed a Part Two on Lying 4:30 Is Compulsive Lying Learned or Genetic? 6:00 A Counselor's Take: It Starts in Childhood 7:00 Why Liars Are So Charming 8:00 White Lies vs. the Lies That Scare You 10:00 When They Double Down on the Evidence 11:00 Fact-Checking & Setting Boundaries 12:00 Lying in Court & Why You Stand on Facts 12:30 Never Delete a Text: Keeping the Receipts 13:30 Gaslighting & "Am I Crazy?" 15:30 Red Flags: Double Lives & Burner Phones 16:30 The 94,000 Screenshots 18:00 Taco Bell or Taco Bueno? 19:00 No Liars in 2026  

There are two ways to provide vitamins, minerals, and amino acids to your horse: through factories or nature. In this episode, I discuss how horses obtain these nutrients naturally and where natural sources fall short. I also explore the production of these nutrients in laboratories and factories. I spend some time looking at where using man-made materials is required due to the environments in which horses live. For example, horses grazing large fields of fresh green grass undoubtedly have different needs than those raised in a dry lot. You will be surprised how adaptive horses can be up to a point. What may be more surprising is how few companies make the ingredients we discuss. Of concern are the many hands in the supply chain, in the production of the final product, and how often they sell the same ingredient under different brand names. 0:01 - Why horses may need supplements. 01:49 - Water: ground versus distilled. 02:17 - Minerals: macro and micro. Common deficiencies. Chelation. Why horses rarely get mineral deficiencies. Thumps (Synchronous Diaphragmatic Flutter), Electrolytes, Rickets, Magnesium deficiency and its associated behavior changes. 09:02 - Protein and amino acid deficiency: Natural versus synthetic amino acids, Signs of an amino acid deficiency, Genetic modification of microorganisms. 13:29 - About 80% of all amino acids and vitamins are made in China—discussion of the supply chain from raw materials to production facilities. 17:15 - The first of two problems: Man-made vitamins and amino acids are either made from chemicals or from genetically modified microorganisms, and the long supply chain from raw materials to the final product in your barn has too many points of non-verifiable steps and materials. 18:32- The second of two problems: How can the deficit or the results of supplementation be verified in the horse? 21:37 - Testing the diet that the horse is eating and comparing that to the signs of deficiencies. 23:21 - The fallacy that placing supplements in the food, other than macronutrients, will fix an underlying energy problem (mitochondria). 25:17 - The chemical in gunpowder that caused increased mitochondrial function and subsequent loss of body fat despite over-eating. It was called DNP (dinitrophenol), which acts as a mitochondrial uncoupler: It disrupts the proton gradient in cells, causing the body to "waste" energy as heat (thermogenesis) instead of storing it as ATP. This ramps up metabolic rate (sometimes by 30–50% or more), leading to rapid fat and carbohydrate breakdown and significant weight loss—even without dieting. (Wikipedia) Banned in 1938 by the FDA. 26:45 - Without the ability to test horses for a deficiency, feed companies just throw in amino acids, vitamins, and minerals to cover any possibilities without any proof they are needed. 29:30 - Vitamin C in humans and horses. 31:06 - Vitamins A, D, E, and K in horses. 33:51 - The B Vitamins. 34:35 - Summary of how and where raw materials are made, and the long supply chain to the final product sold to horse owners. Look at the horse for a deficiency. Look at the diet for deficiencies. Protein deficiency is the most common one seen, with the most problems in horses due to the lack of protein. Remove ingredients that inflame the gut. ******************************* #horses #veterinary #horseteeth #horsecare #equinedentistry Join us at The Horses Advocate Community page: https://community.thehorsesadvocate.com/yt Dentistry: https://theequinepractice.com/ Horsemanship Dentistry School: https://www.horsemanshipdentistryschool.com/c/information/ Facebook: https://www.facebook.com/TheHorsesAdvocate Instagram: https://www.instagram.com/horsesadvocate/ Geoff Tucker is a veterinarian and horseman who has worked with horses since 1973. He earned his Doctor of Veterinary Medicine from Cornell University in 1984. Over the years, Geoff went from mucking stalls as a farmhand to starting his own equine practice. This journey helped him learn how to blend medical care with good horsemanship. Geoff believes in doing what is best for the horse and also in working with the horse. While at Cornell, he started the Cornell Student Horseman's Association, which organized talks with local experts, a knowledge competition called the Intercollegiate Horse Bowl, and Foal Watch at the Equine Research Park to help with live foal deliveries. Wanting to educate horse owners even more, Geoff also launched the first "I Love New York Horse Symposium," which drew 500 people from across the northeast. Geoff also worked at the Equine Isolation Lab alongside respected colleagues, including Dr. Coggins, whose name is on the well-known test. He worked both part-time and full-time at Cornell's Equine Research Park. On graduation day in 1984, while his classmates celebrated, Geoff drove his fully stocked vet truck to his first call—a sick foal. This marked the beginning of The Finger Lakes Equine Practice, which still operates today. Geoff sold the practice in 1996, worked for a short time at another clinic near Albany, NY, and then started The Equine Practice, focusing on equine dentistry. He continues this work from his base in South Florida. Geoff worked on his first horse's teeth in 1983, when his mentor showed him how to place his hand inside a horse's mouth without medication and rasp off the offending sharp points. He was hooked from the start and made dentistry a key part of his practice. Since then, he has examined the mouths of over 84,000 horses across the United States - yes, he's been counting.

In this episode, Dr. Marc Pietropaoli discusses his transition from traditional orthopedics to regenerative medicine, emphasizing the importance of repairing rather than replacing damaged joints. He shares insights on the components and sequencing of regenerative treatments, the role of genetic testing in nutrition, and his mission to eliminate the need for knee replacements by 2043. The conversation highlights the significance of prevention and proactive care in joint health. In this conversation, Dr. Marc Pietropaoli discusses various aspects of injury prevention, particularly focusing on ACL injuries and innovative surgical techniques. He emphasizes the importance of proper landing techniques, dynamic warm-ups, and the role of proprioception in preventing injuries. The discussion also covers the advancements in ACL repair, including the bear procedure, which utilizes a collagen implant to enhance healing and reduce the risk of arthritis. The conversation concludes with resources for further learning and insights into the future of sports medicine.   For Audience Join the other 20,000+ high-performers getting weekly insights on biological reversal, exponential strategies, and Life Energy optimization→ https://start.gladdenlongevity.com/subscribe If you're ready to measure your 60+ biological ages and build a personalized reversal plan, apply for a discovery call here → https://start.gladdenlongevity.com/apply-now   Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/!      Takeaways        Dr. Pietropaoli transitioned from traditional orthopedics to regenerative medicine.        He emphasizes the body's ability to heal itself through regenerative techniques.        The importance of asking questions in medical training is highlighted.        Dr. Pietropaoli's personal experiences influenced his career path.        He advocates for a team approach in patient care, involving various specialists.        Inflammation is a key factor in joint health and must be addressed.        Genetic testing can guide nutritional choices for better health outcomes.        Preventive measures can significantly reduce the risk of joint injuries.        Dr. Pietropaoli aims to end the need for knee replacements by 2043.       The conversation underscores the importance of patient education in exploring treatment options. Bending knees during landing reduces injury risk.        Proper proprioception is crucial for athletes.        Dynamic warm-ups are more effective than static stretching.        Mastering two-legged exercises is essential before progressing to one-legged ones.        Plyometrics enhance fast twitch muscle fiber development.        Agility is linked to balance and quickness.        Bear surgery offers a promising alternative to traditional ACL repair.        Collagen implants can significantly aid in ACL healing.        Using blood flow restriction can enhance recovery post-surgery.        Education and awareness are key in sports injury prevention.     Chapters 00:00 Introduction to Regenerative Orthopedics 04:08 The Journey from Traditional to Regenerative Medicine 13:46 Components and Sequencing in Regenerative Treatments 20:04 Genetic Testing and Nutrition for Optimal Health 22:52 Future Aspirations in Joint Health and Prevention 27:09 Injury Prevention Techniques 34:06 Understanding ACL Injuries and Repair 42:35 Innovations in ACL Surgery 45:34 Resources and Final Thoughts   To learn more about Dr. Marc: Website: www.victoryinmotion.com TikTok: https://www.tiktok.com/@drmarcpietropaoli Instagram: https://www.instagram.com/drmarcpietropaoli LinkedIn: https://www.linkedin.com/in/drmarcpietropaoli YouTube: https://www.youtube.com/@victoryinmotion1   Reach out to us at:    Website: https://gladdenlongevity.com/     Facebook: https://www.facebook.com/Gladdenlongevity/    Instagram: https://www.instagram.com/gladdenlongevity/?hl=en     LinkedIn: https://www.linkedin.com/company/gladdenlongevity    YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw     Gladden Longevity Podcast Disclosures Production & Independence The Gladden Longevity Podcast and Age Hackers are produced by Gladden Longevity Podcast, which operates independently from Dr. Jeffrey Gladden's clinical practice and research at Gladden Longevity in Irving, Texas. Dr. Gladden may serve as a founder, advisor, or investor in select health, wellness, or longevity-related ventures. These may occasionally be referenced in podcast discussions when relevant to educational topics. Any such mentions are for informational purposes only and do not constitute endorsements. Medical Disclaimer The Gladden Longevity Podcast is intended for educational and informational purposes only. It does not constitute the practice of medicine, nursing, or other professional healthcare services — including the giving of medical advice — and no doctor–patient relationship is formed through this podcast or its associated content. The information shared on this podcast, including opinions, research discussions, and referenced materials, is not intended to replace or serve as a substitute for professional medical advice, diagnosis, or treatment. Listeners should not disregard or delay seeking medical advice for any condition they may have. Always seek the guidance of a qualified healthcare professional regarding any questions or concerns about your health, medical conditions, or treatment options. Use of information from this podcast and any linked materials is at the listener's own risk. Podcast Guest Disclosures Guests on the Gladden Longevity Podcast may hold financial interests, advisory roles, or ownership stakes in companies, products, or services discussed during their appearance. The views expressed by guests are their own and do not necessarily reflect the opinions or positions of Gladden Longevity, Dr. Jeffrey Gladden, or the production team. Sponsorships & Affiliate Disclosures To support the creation of high-quality educational content, the Gladden Longevity Podcast may include paid sponsorships or affiliate partnerships. Any such partnerships will be clearly identified during episodes or noted in the accompanying show notes. We may receive compensation through affiliate links or sponsorship agreements when products or services are mentioned on the show. However, these partnerships do not influence the opinions, recommendations, or clinical integrity of the information presented. Additional Note on Content Integrity All content is carefully curated to align with our mission of promoting science-based, ethical, and responsible approaches to health, wellness, and longevity. We strive to maintain the highest standards of transparency and educational value in all our communications.  

For decades, people diagnosed with Crohn's disease and ulcerative colitis have been told the same three things: the disease is genetic, autoimmune, and ultimately idiopathic—meaning nobody truly knows what causes it. But does today's scientific literature actually support those conclusions? Josh explains how the very terminology of those 3 words "genetic", "autoimmune", "random" is actually based on misinterpreted or ignored science, and that the narrative of it being impossible to fix, stops people from bothering to look. In this episode, he breaks down the history, the studies and the science to prove that bowel disease is not what they say it is.   TOPICS DISCUSSED: Challenging the genetic theory of IBD Questioning the autoimmune classification Environmental and lifestyle risk factors Historical evolution of IBD research Genetics vs. gene expression (environmental influence) Remission versus cure debate   If you have Crohn's, Colitis or Diverticulitis, be sure to check out my second podcast: Reversing Crohn's and Colitis Naturally.   Leave us a Review: https://www.reversablepod.com/review   Need help with your gut? Visit my website gutsolution.ca to join a program: Get help now   Contact us: reversablepod.com/tips    FIND ME ON SOCIAL MEDIA: Instagram  Facebook  YouTube

Bruce Lipton returns with a claim that should change how you run your life: 95% of your day is driven by subconscious programs installed before you turned seven, and once you can see them, you can rewrite them. The cell biologist behind The Biology of Belief lays out how belief quietly shapes your health, your wealth, and your relationships, and exactly how to take that power back.In this conversation Bruce hands Aubrey the working manual: the three proven ways to reprogram a limiting belief, how muscle testing surfaces the hidden program sabotaging you, and why willpower fades the moment you stop pushing while reprogramming holds for good. He makes the case that there is no real limit on what belief can do to the body, that no gene condemns you to the disease running in your family, and that you are the creator of the reality you're living. It builds into a master class in becoming the author of your own biology, and closes on the line that reframes everything: Darwin was wrong, the Bible was wrong, and the environment has been writing us all along.We discuss: – the 95/5 split between your creative mind and your subconscious, and how to flip it – the three ways to reprogram a limiting belief – muscle testing and the hidden program sabotaging your goals – why willpower fails where reprogramming lasts – the honeymoon effect and the mind's creative power – why no gene dooms you to your family's disease – the real outer limits of belief on the body – becoming a conscious parent when 95% of your day runs on autopilot| Bruce Lipton | ►Website | https://www.brucelipton.com/►Instagram | https://www.instagram.com/brucelipton►YouTube | https://www.youtube.com/user/biologyofbeliefThis episode is sponsored by►Metal Mark Gold Aurum Collectable Art | ⁠https://mtlmrk.com/⁠►Korrect Life | ⁠https://korrectlife.com/| Aubrey Marcus |►Website | ⁠⁠https://www.aubreymarcus.com/►Instagram | https://www.instagram.com/aubreymarcus►Facebook |⁠⁠ https://www.facebook.com/AubreyMarcus/►X |⁠ https://x.com/aubreymarcus►Substack: https://www.aubreymarcus.com/blogs/substack► Love To The Seventh Power: ⁠https://chakaruna.com/collections/books⁠Subscribe to the Aubrey Marcus podcast:►iTunes |⁠ ⁠⁠⁠⁠⁠⁠https://apple.co/2lMZRCn ⁠⁠⁠⁠⁠⁠⁠►Spotify |⁠⁠⁠⁠⁠⁠⁠ https://spoti.fi/2EaELZO ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠►IHeartRadio |⁠ ⁠⁠⁠⁠⁠⁠https://ihr.fm/3CiV4x3 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠►Partner with the Aubrey Marcus Podcast | https://www.aubreymarcus.com/pages/booking

Why are billionaires building bunkers in the mountains? Why did Germany mandate underground shelters? Why did Russia run a drill to get 40 million people underground in twelve hours? Jamie Walden says they all know something, and it has a name. Apophis. He returns to Blurry Creatures to connect the asteroid coming in 2029 to the book of Revelation, and to argue that almost everything strange about the last six years traces back to one event. 2020. The Great Reset. Genetic data banks. The push for underground cities. Jamie frames it as a counterfeit ark, a man-made attempt to choose who survives what God already promised was coming. It sounds overwhelming, and it is. But Jamie does not hand you fear. He hands you the gospel instead. The asteroid may or may not be Wormwood. The real question is whether you believe God is good. This episode is sponsored by: https://ruffgreens.com — Get a free Jumpstart Trial bag with discount code BLURRY at checkout. http://blurrygold.com/ — Get a FREE Gold & Silver Kit while supplies last! https://homechef.com/blurry — Get 50% off plus free shipping on your first box & free dessert for life! - Learn more about your ad choices. Visit megaphone.fm/adchoices

Fish Oil Supplements And Alzheimer's-Related Decline A two-year randomized, double-blind, placebo-controlled trial led by researchers at USC tested whether 2,000 mg of DHA fish oil daily could slow Alzheimer's-related brain changes in 365 adults ages 55–80 who rarely consumed fish and had at least one Alzheimer's risk factor. Researchers confirmed the supplement reached the brain by measuring a roughly 17% increase in cerebrospinal fluid DHA after six months. Despite successfully increasing brain DHA levels, participants taking fish oil showed no significant improvements in memory, global cognitive function, or hippocampal volume compared to placebo after two years. Host Dave Asprey explains why raising a single biomarker doesn't always translate into better brain performance, why nutrition works differently inside a complete dietary pattern than as an isolated supplement, and what this study means for anyone relying on fish oil as an Alzheimer's prevention strategy. Sources: https://medicalxpress.com/news/2026-06-fish-oil-supplements-alzheimer-decline.pdf https://www.cnn.com/2026/06/18/health/omega-3-fish-oil-algae-supplement-wellness ~~ DASH Diet Showed the Strongest Link to Long-Term Brain Health Researchers from Harvard analyzed dietary data from 159,347 participants across three long-running U.S. health studies to examine how eating patterns influence cognitive aging. Participants completed dietary questionnaires every four years over several decades, allowing investigators to compare six healthy dietary patterns, including the DASH and Mediterranean diets. While all six were associated with better cognitive health later in life, adherence to the DASH diet produced the strongest association, with participants showing roughly a 40% lower risk of subjective cognitive decline and stronger performance on objective cognitive testing. The protective relationship was strongest when healthy eating habits began during midlife. Host Dave Asprey breaks down why blood sugar control, lower inflammation, and healthier blood vessels may be the real drivers behind long-term brain resilience, and why your dietary choices in your 40s and 50s may have an outsized impact on cognitive aging decades later. Sources: https://jamanetwork.com/journals/jamaneurology/article-abstract/2845466 https://www.health.harvard.edu/diet-and-nutrition/harvard-study-six-healthy-diets-linked-with-better-long-term-brain-health https://www.eurekalert.org/news-releases/1117225 ~~ Scientists Identified an Ancient Brain Circuit That Filters Distractions Johns Hopkins researchers discovered a small population of inhibitory neurons within an evolutionarily ancient brainstem region that appears to control selective attention by determining which sensory information deserves focus and which distractions should be ignored. Mice trained on visual attention tasks consistently ignored irrelevant stimuli until researchers temporarily silenced these neurons, causing even weak distractions to hijack their attention while leaving vision and movement otherwise unaffected. Similar brain circuits exist in birds, reptiles, and other vertebrates, suggesting this attentional filtering system evolved long before the modern human cortex. Host Dave Asprey explains why attention may depend on much older brain circuitry than previously believed, how this discovery could reshape our understanding of ADHD and autism, and why future therapies may target the brainstem instead of the prefrontal cortex. Sources: https://www.sciencedaily.com/releases/2026/06/260624025426.htm ~~ Nearly Half of Older Adults Improved With Age Instead of Declining A Yale-led study followed 11,340 adults age 65 and older for up to 12 years using repeated measurements of cognition and walking speed to better understand how aging changes over time. Rather than finding universal decline, researchers discovered that 45% of participants improved in either cognitive function, physical performance, or both. Nearly one-third experienced measurable cognitive improvements, while over one-quarter improved physically. Researchers also found that participants with more positive beliefs about aging were significantly more likely to improve, even after accounting for education, chronic illness, depression, and other health factors. Host Dave Asprey explores why expectations about aging may become biologically embedded, why decline is far less inevitable than conventional medicine often assumes, and how mindset may directly influence healthy longevity. Sources: https://www.sciencedaily.com/releases/2026/06/260620100428.htm ~~ Glyphosate May Be Contributing to Antibiotic-Resistant Superbugs Researchers publishing in Frontiers in Microbiology examined 102 bacterial strains collected from hospitals, agricultural land, and protected wetlands to investigate whether glyphosate exposure contributes to multidrug antibiotic resistance. Hospital bacteria demonstrated extensive resistance to both antibiotics and glyphosate, while even bacteria living inside protected nature reserves displayed measurable glyphosate resistance despite no direct herbicide application. Genetic analysis suggested resistant bacterial strains may move between agricultural environments and hospitals through shared waterways and sediments. The researchers argue pesticide safety testing should also evaluate whether chemicals encourage antibiotic resistance, one of the world's fastest-growing public health threats. Host Dave Asprey explains why environmental toxins may have unintended effects on the human microbiome, how herbicides could influence antimicrobial resistance beyond farming, and why environmental biology increasingly belongs in conversations about human health. Sources: https://www.sciencedaily.com/releases/2026/06/260620100434.htm https://www.openaccessgovernment.org/common-weedkiller-glyphosate-linked-to-rise-in-superbugs-scientists-warn/207515/ ~~ Butterflies That Barely Age Could Unlock New Longevity Pathways Researchers from the University of Bristol found that Heliconius butterflies live dramatically longer than closely related butterfly species while aging much more slowly. In one comparison, Heliconius hewitsoni survived up to 348 days, while a closely related species lived only 14 days. Unlike most butterflies, Heliconius feed on pollen throughout adulthood, providing amino acids that help preserve muscle function and physical performance with age. However, even when pollen was removed, these butterflies still significantly outlived their relatives, suggesting evolved genetic and metabolic mechanisms also contribute to their exceptional longevity. Host Dave Asprey explores why nature continues to provide unexpected models for slowing biological aging, what scientists hope to learn from species that naturally maintain function over time, and how comparative biology may uncover entirely new pathways for extending human healthspan. Sources: https://www.sciencedaily.com/releases/2026/06/260622014302.htm ~~ This episode is designed for biohackers, longevity enthusiasts, and high-performance listeners who want mechanism-level insights into omega-3 supplementation and Alzheimer's prevention, nutrition strategies for preserving cognitive health, newly discovered brain circuits controlling attention, the surprising biology behind healthy aging, environmental drivers of antibiotic resistance, and what one remarkably long-lived butterfly can teach us about extending healthspan. Host Dave Asprey connects randomized clinical trials, large population studies, neuroscience discoveries, microbiology research, and evolutionary biology into practical frameworks for improving brain performance, resilience, and longevity. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: fish oil Alzheimer's study, DHA supplements memory, omega-3 brain health, DASH diet cognition, dementia prevention diet, cognitive decline nutrition, selective attention brainstem, focus neuroscience, ADHD brain research, positive aging beliefs, healthy aging study, cognitive improvement older adults, glyphosate antibiotic resistance, superbugs glyphosate, environmental toxins microbiome, butterfly longevity research, Heliconius aging, longevity science, biohacking news 2026, Dave Asprey, The Human Upgrade Thank you to our sponsors! - Suppgrade Labs | Grab your DAKE and Minerals 101 duo at shopsuppgradelabs.com and use code DAVEPOD for 15% off today - Neuronic | Go to www.neuronic.online Code DAVE for $100 off - iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Intro 00:18 – Story #1 Fish Oil 02:31 – Story #2 DASH Diet 03:49 – Story #3 Brain Stem Attention Filter 05:59 – Story #4 Cognitive Decline Lies 08:24 – Story #5 Glyphosate 10:16 – Story #6 Butterfly Lifespan Research 12:16 – Biohacking Criticism Response See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.